NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, particularly to naphthylamide compounds, medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comprising the compounds and the uses thereof as protein tyrosine kinase inhibitors, particularly as VEGFR-2 inhibitors, in preparing drugs for preventing and treating diseases related to abnormal angiogenesis.

Background Art

[0002] Angiogenesis (Angiogenesis), i.e., new blood vessel constructed from existing blood vessel, is an important mechanism of many physiological and pathological processes occurrence. Under normal circumstances, angiogenesis occurs only in embryonic development, wound healing and menstrual cycles of women. Abnormal angiogenesis may occur under pathological conditions (Shibuya M. BMB. Rep. 2008; 41(4): 278-86), especially during the growth of tumors which requires new blood vessels to supply nutrients and excrete metabolites. Endothelial proliferation and new blood vessel formation promote an increase in solid tumors.

[0003] The key signal system regulates endothelial cell proliferation and migration is vascular endothelial growth factor (VEGF) and its receptor (VEGFR-1, -2 and -3). VEGFR-2 has a higher affinity and kinase activity, and plays a more important role in directly regulating angiogenesis, mitogenic signaling and permeability increasement. Vascular endothelial growth factor receptors (VEGFRs) are expressed at high levels in many human solid tumors, including glioma, lung cancer, breast cancer, renal cancer, ovarian cancer and gastrointestinal cancer.

[0004] VEGF/VEGFR-2 signaling pathway plays a critical role in tumor angiogenesis, and can inhibit angiogenesis by blocking or interfering with VEGF/VEGFR-2 signaling pathway in order to achieve the effect of controlling the growth of tumors. Thus, many small molecule VEGFR-2 inhibitors are being developed, some of which are useful in treating angiogenesis disorder related disease such as inflammatory diseases, retinopathy and so on. The present inventors have designed and synthesized naphthalene amides having novel structures and found small molecule VEGFR-2 inhibitors having good activity in the enzyme level and cellular level by optimizing the substituents.

Summary of the invention

[0005] In the present inventipon, a series of novel compounds were designed and synthesized by studing the crystal structure of VEGFR-2 and structure-activity relationship of other tyrosine kinase inhibitor, and screened by molecular and cellular screening model. These compounds can significantly inhibit the enzymic activity of VEGFR-2 at molecular level and significantly inhibit VEGF-induced human umbilical vein endothelial cells (HUVEC) proliferation at cellular level.

[0006] One object of the present invention is to provide naphthylamide compounds as represented by formula (I), medicinal salts, and hydrates or solvates thereof:

[0007] Another object of the present invention is to provide a method for preparing the above naphthylamide compounds.

[0008] A further object of the present invention is to provide a pharmaceutical composition containing a therapeutically effective amount of one or more of above naphthylamide compounds, medicinal salts, and hydrates or solvates thereof.

[0009] A further object of the present invention is to provide a use of one or more of above naphthylamide compounds, medicinal salts, and hydrates or solvates thereof as protein tyrosine kinase inhibitor, especially as a VEGFR-2 inhibitor, in the preparation of drugs for preventing and/or treating diseases associated with aberrant angiogenesis.

[0010] More specifically, the present invention relates to naphthylamide compounds of general formula (I), medicinal salts, and hydrates or solvates thereof;

wherein,

R₁ may be located at any one of 5-8 positions on the naphthalene ring, and is a substituted or unsubstituted 5-16 membered monocyclic, dicyclic or tricyclic heteroaryl containing 1-5 hetero atoms selected from the group comprising N, O, S and P, preferably is a substituted or unsubstituted 5-10 membered monocyclic or dicyclic heteroaryl containing 1-3 hetero atoms selected from the group comprising N, O and S, more preferably a substituted or unsubstituted group as follows: pyrazolyl, furyl, pyrrolyl, pyridyl, indazolyl (e.g., 1H-indazolyl, 2H-indazolyl), furo[3,2-c]pyridyl, thieno[3,2-c]pyridyl, thieno[2,3-d]pyrimidinyl, benzo[d] isoxazolyl, benzo[d]isothiazolyl, indolyl, quinolyl or isoquinolyl; most preferably a substituted or unsubstituted group as follows: indazolyl (eg, 1H-indazolyl), furo[3,2-c]pyridyl, thieno[3,2 -c]pyridyl or thieno[2,3-d]pyrimidinyl, benzo[d]isoxazolyl; in the case of substitution, the substituent may be 1 to 3 substituents, said substituent is independently selected from the group comprising amino, C1-C3 alkyl, C1-C3 alkoxy, halogen, pyrazolyl, C1-C3 alkyl-substituted pyrazolyl, C1-C3 hydroxyalkyl-substituted pyrazolyl, preferably amino, methyl, methoxy, F, Cl, Br, pyrazolyl, methyl-substituted pyrazolyl and hydroxyethyl-substituted pyrazolyl;

in most preferred embodiment, R₁ is the following structure:

wherein, R₄ is selected from the group comprising hydrogen, halogen, C1-C3 alkyl and C1-C3 alkoxy, preferably selected from the group comprising hydrogen, F, Cl, Br, methyl and methoxy;

may be located at any one of 1-4 positions on the naphthalene ring;

R₃ is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-10 membered heteroaryl containing 1-5 hetero atoms selected from N, O and S, preferably selected from the group consisting of hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl, a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-6 membered heteroaryl containing 1-3 hetero atoms selected from N, O and S; more preferably selected from the group consisting of hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl and a substituted or unsubstituted following group: phenyl, pyridyl, pyrimidinyl, oxazolyl, isoxazolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, furyl and pyrrolyl; most preferably selected from the group consisting of hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl and a substituted or unsubstituted following group: phenyl, pyridyl, oxazolyl and isoxazolyl; in the case of substitution, the substituent may be 1 to 3 substituents and each substituent is independently selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, hydroxy, amino, nitro, and halogen; preferably selected from the group consisting of C1-C3 alkyl, methoxy, trifluoromethyl, trifluoromethoxy, hydroxy, amino, nitro, F, Cl and Br;

R2 can be located at any one of positions 1-8 on the naphthalene ring except R₁ and

, and is hydrogen or halogen; preferably hydrogen, F, Cl or Br.

[0011] Preferably, the naphthylamide compounds represented by general formula (I) are compounds represented by following formula (II):

wherein, R₂ and

are defined as described in general formula (I);

Z is C(R₅)=CH, S or O;

Y is NH, NMe, O, CH=C(R₆) or CH=N;

R₅ is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl and C1-C3 alkoxy, preferably from the group consisting of hydrogen, F, Cl, Br, methyl and methoxy; R₆ is selected from the group consisting of hydrogen, pyrazolyl, alkyl-substituted pyrazolyl and hydroxyalkyl-substituted pyrazolyl, preferably from the group consisting of hydrogen, pyrazolyl, methyl-substituted pyrazolyl and hydroxyethyl-substituted pyrazolyl.

[0012] Preferably, naphthylamide compounds represented by general formula (I) are selected from the compounds represented by the following general formula:



wherein,

can be located at position 1 or 2 on the naphthalene ring; R₂ and R₃ are defined as described in general formula (I); R₄ is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy, preferably from the group consisting of hydrogen, F, Cl, Br, methyl and methoxy;

V is S or O;

W is N or C(R₇);

R₇ is selected from the group consisting of hydrogen, pyrazolyl, alkyl-substituted pyrazolyl and hydroxyalkyl-substituted pyrazolyl, preferably from the group consisting of hydrogen, pyrazolyl, methyl-substituted pyrazolyl and hydroxyethyl-substituted pyrazolyl.

[0013] Preferably, naphthylamide compound represented by general formula (I) in the present invention is selected from the compounds shown in Table 1:

Table 1

compound	name	structural formula
1-1	6-(3-amino-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxami de
1-2	6-(4-aminofuro[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalenecarb oxamide
I-3	6-(4-aminothieno[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalenecar boxamide
I-4	6-(4-aminothieno[2,3-d]pyrimidi n-5-yl)-N-phenyl-1-naphthalenec arboxamide
I-5	6-(4-amino-7-(1-(2-hydroxyethyl )-1H-pyrazol-4-yl)thieno[3,2-c]p yridin-3-yl)-N-phenyl-1-naphtha lenecarboxamide
I-6	6-(3-amino-1H-indazol-4-yl)-N-( o-methylphenyl)-1-naphthalenec arboxamide
I-7	6-(3-amino-1H-indazol-4-yl)-N-( m-methylphenyl)-1-naphthalene carboxamide
I-8	6-(3-amino-1H-indazol-4-yl)-N-( p-methylphenyl)-1-naphthalenec arboxamide
I-9	6-(3-amino-1H-indazol-4-yl)-N-( 3-ethylphenyl)-1-naphthalenecar boxamide
I-10	6-(3-amino-1H-indazol-4-yl)-N-( 2-fluorophenyl)-1-naphthaleneca rboxamide
I-11	6-(3-amino-1H-indazol-4-yl)-N-( 3-fluorophenyl)-1-naphthaleneca rboxamide
I-12	6-(3-amino-1H-indazol-4-yl)-N-( 4-fluorophenyl)-1-naphthaleneca rboxamide
I-13	6-(3-amino-1H-indazol-4-yl)-N-( 2,4-difluorophenyl)- 1 -naphthale necarboxamide
I-14	6-(3-amino-1H-indazol-4-yl)-N-( 3,5-difluorophenyl)-1-naphthale necarboxamide
I-15	6-(3-amino-1H-indazol-4-yl)-N-( 3-chlorophenyl)-1-naphthaleneca rboxamide
I-16	6-(3-amino-1H-indazol-4-yl)-N-( 3-bromophenyl)-1-naphthalenec arboxamide
I-17	6-(3-amino-1H-indazol-4-yl)-N-( 3,5-dichlorophenyl)- 1-naphthale necarboxamide
I-18	6-(3-amino-1H-indazol-4-yl)-N-( 3,5-dibromophenyl)-1-naphthale necarboxamide
I-19	6-(3-amino-1H-indazol-4-yl)-N-( 3-(trifluoromethyl)phenyl)-1-nap hthalenecarboxamide
I-20	6-(3-amino-1H-indazol-4-yl)-N-( 2-fluoro-5-methylphenyl)- 1-nap hthalenecarboxamide
I-21	6-(3-amino-1H-indazol-4-yl)-N-( 4-fluoro-3-methylphenyl)-1-nap hthalenecarboxamide
I-22	6-(3-amino-1H-indazol-4-yl)-N-( 2-fluoro-4-methylphenyl)-1-nap hthalenecarboxamide
I-23	6-(3-amino-1H-indazol-4-yl)-N-( 3-fluoro-4-methylphenyl)- 1-nap hthalenecarboxamide
I-24	6-(3-amino-1H-indazol-4-yl)-N-( 5-methylisoxazol-3-y1)-1-naphth alenecarboxamide
I-25	6-(3-amino-1H-indazol-4-yl)-N-( pyridin-3-yl)-1-naphthalenecarb oxamide
I-26	6-(3-amino-1H-indazol-4-yl)-N-ethyl-1-naphthalenecarboxamide
I-27	6-(3-amino-1H-indazol-4-yl)-N-cyclopropyl-1-naphthalenecarbo xamide
I-28	6-(3-amino-1H-indazol-4-yl)-5-f luoro-N-phenyl-1 -naphthaleneca rboxamide
I-29	6-(3-amino-1-methyl-1H-indazol -4-yl)-N-phenyl-1-naphthaleneca rboxamide
I-30	6-(3-amino-1H-indazol-4-yl)-N-phenyl-2-naphthalenecarboxami de
I-31	6-(3-amino-1H-indazol-4-yl)-5-f luoro-N-phenyl-2-naphthaleneca rboxamide
I-32	6-(3-amino-1H-indazol-4-yl)-5-c hloro-N-phenyl-1 -naphthaleneca rboxamide
I-33	6-(3-amino-7-fluoro-1H-indazol-4-yl)-N-phenyl-1-naphthalenecar boxamide
I-34	6-(3-amino-7-bromo-1H-indazol -4-yl)-N-phenyl-1-naphthaleneca rboxamide
I-35	6-(3-amino-7-methyl-1H-indazol -4-yl)-N-phenyl-1-naphthaleneca rboxamide
I-36	6-(3-amino-1H-indazol-4-yl)-N-( 3-methoxyphenyl)-1-naphthalen ecarboxamide
I-37	6-(3-amino-1H-indazol-4-yl)-N-( 3-(trifluoromethoxy)phenyl)-1-n aphthalenecarboxamide
I-38	6-(3-amino-1H-indazol-4-yl)-N-( 3-hydroxyphenyl)- 1 -naphthalene carboxamide
I-39	6-(3-amino-1H-indazol-4-yl)-N-( 3-nitrophenyl)- 1-naphthalenecar boxamide
I-40	6-(3-amino-1H-indazol-4-yl)-N-( 3-aminophenyl)-1-naphthaleneca rboxamide
I-41	6-(3-aminobenzo[d]isoxazol-4-yl )-N-phenyl-1-naphthalenecarbox amide
I-42	6-(3-amino-7-fluorobenzo[d]isox azol-4-yl)-N-phenyl-1-naphthale necarboxamide
I-43	6-(3-amino-7-methylbenzo[d]iso xazol-4-yl)-N-phenyl-1-naphthal enecarboxamide
I-44	6-(3-amino-7-methoxybenzo[d]i soxazol-4-yl)-N-phenyl-1-naphth alenecarboxamide

[0014] The pharmaceutically acceptable salts of the compounds of the present invention may be prepared through direct salt forming reaction of free base of compound and inorganic or organic acid. Inorganic or organic acid may be selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, picric acid, citric acid, maleic acid, methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid.

[0015] The present invention also relates to a preparation method of naphthylamide compounds of general formula (I), for example, including the following steps:

[0016] Starting from compound 1, hydroxyl was reacted to form triflate, and then to form borate. Naphthalate was hydrolyzed, then condensed with the corresponding ammonia/amine to obtain naphthylamide borate and finally coupled with a heteroaryl halide to give the target compound.

[0017] Specifically, the preparation method comprises the steps of:

1) Compound 1 is reacted with trifluoromethanesulfonic anhydride under basic condition to give compound 2;

2) Compound 2 and bis(pinacolato)diboron are subjected to coupling reaction in the presence of a palladium catalyst to obtain boronate 3;

3) Compound 3 was hydrolyzed with lithium hydroxide or sodium hydroxide to obtain compound 4;

4) Compound 4 and the corresponding ammonia/amine R₃NH₂ are subjected to condensation reaction under the effect of condensation agent such as dicyclohexyl carbodiimide (DCC), 1- (3-dimethylaminopropyl)-3-ethyl carbodiimide (EDC), 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDCI) or N,N'-diisopropyl carbodiimide (DIC) to obtain compound 5;

5) Compound 5 and the corresponding heteroaryl halide R₁X are subjected to coupling reaction in the presence of a palladium catalyst to obtain the objective compound (I);

wherein, R₁, R₂ and R₃ are defined and preferred as above, X is halogen, preferably, Br or I.

[0018] The preparation method of naphthylamide compounds of the present invention has advantages such as mild reaction condition, abundant accessible raw materials, simple operation and post-processing and the like.

[0019] The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of one or more of naphthylamide compounds of formula (I), pharmaceutically acceptable salts, hydrates and solvates thereof, and optionally a pharmaceutically acceptable carrier, which may be used in prevention and/or treatment of abnormal angiogenesis-related diseases. The pharmaceutical compositions may be prepared in various forms depending on different route of administration.

[0020] The present invention also relates to use of one or more of naphthylamide compounds of formula (I), pharmaceutically acceptable salts, hydrates and solvates thereof, or pharmaceutical composition comprising a therapeutically effective amount of one or more of naphthylamide compounds of formula (I), pharmaceutically acceptable salts, hydrates and solvates thereof in the preparation of drugs for the prevention and/or treatment of abnormal angiogenesis-related diseases, preferably as protein tyrosine kinase inhibitors, especially as VEGFR-2 inhibitors.

[0021] Wherein, the abnormal angiogenesis-related disease is selected from the group consisting of tumor, rheumatoid arthritis, age-related macular degeneration and psoriasis.

[0022] The tumor includes lung cancer, breast cancer, colon cancer, prostate cancer, pancreatic cancer, stomach cancer, liver cancer, ovarian cancer, renal cancer, glioma, melanoma, pancreatic cancer, head and neck cancer, bladder cancer, cervical cancer, cholangiocarcinoma, nasopharyngeal cancer, thyroid cancer, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, fibrosarcoma, leiomyosarcoma, myeloma, lymphoma.

Detailed description

[0023] The present invention will be further illustrated by the following examples. These examples are intended to illustrate the present invention,

[0024] The subject-matter of the present invention is as defined in the appended set of claims. Unless otherwise defined or stated, all professional and scientific terms used herein have same meanings known as the skilled in the art.

Example 1:

6-(3-amino-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (1-1)

[0025] 

Step 1: methyl 6-(trifluoromethylsulfonyloxy)-1-naphthoate

[0026] 5g of 6-hydroxy-1-naphthoic acid was dissloved in 200 ml of methanol, and 2.8 ml of thionyl chloride was added dropwise with stirring. The mixture was heated under reflux for 2 hours, then cooled to room temperature and concentrated under reduced pressure to give methyl 6-hydroxy-1-naphthoate as tan solid which was directly used to the next step. 2.5 g of methyl 6-hydroxy-1-naphthoate was dissloved in 150 ml of dichloromethane and 6.5 ml of diisopropylethylamine and 3 ml of trifluoromethanesulfonic anhydride were added dropwise with stirring at -78 °C. The mixture was stirred at -78 °C for another 1 hour and 100 ml of saturated aqueous ammonium chloride solution was poured in. The organic phase was separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 5: 95) to give 3.5 g methyl 6-(trifluoromethylsulfonyloxy)-1-naphthoate as tan solid. Yield: 93%.

[0027] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 3.97 (s, 3H), 7.74-7.81 (m, 2H), 8.27 (dd, J = 7.2, 1.2 Hz, 1H), 8.30 (d, J = 3.0 Hz, 1H), 8.36 (d, J = 8.1 Hz, 1H), 8.94 (d, J = 9.3 Hz, 1H).

Step 2: methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate

[0028] 3g of methyl 6-(trifluoromethylsulfonyloxy)-1-naphthoate, 2.74 g of bis(pinacolato) diboron, 675 mg of [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), 498 mg of 1,1'-bis(diphenyphosphino)ferrocene, 2.87 g of potassium acetate and 60 ml of dioxane were added to the reaction flask, heated to 80 °C under Ar, stirred for 4 h and then cooled to room temperature. Water and ethyl acetate were added to separate. The aqueous phase was extracted with ethyl acetate. The combined organic phases was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 5: 95) to give 2.74 g of methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoateas brown oil.Yield: 98%.

[0029] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 4.01 (s, 3H), 7.50 (t, J = 7.5 Hz, 1H), 7.97 (dd, J = 8.7, 1.2 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 8.22 (dd, J = 7.5, 1.2 Hz, 1H), 8.40 (s, 1H), 8.88 (d, J = 9.0 Hz, 1H).

Step 3: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid

[0030] 2.74 g of methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate was dissloved in 27 ml of tetrahydrofuran and 27 ml of water and 1.11 g of lithium hydrate was added with stirring. The mixture was stirred at room temperature for 12 h, then acidified with 2 mol/L hydrochloric acid and extracted with ethyl acetate. The combined organic phases was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (methanol: dichloromethane = 3: 97) to give 2.04 g of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid as faint yellow solid.Yield: 78%.

[0031] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.41 (s, 12H), 7.55 (t, J = 8.1 Hz, 1H), 7.80 (dd, J = 8.4, 1.2 Hz, 1H), 8.13 (d, J = 8.1 Hz, 1H), 8.43-8.46 (m, 2H), 9.05 (d, J = 8.7 Hz, 1H).

Step 4: N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene -carboxamide

[0032] 80 mg of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid was dissloved in 8 ml of dichloromethane and 39 mg of 4-dimethylaminopyridine, 77 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride were successively added with stirring at 0 °C. After 15 minutes, 27 microliters aniline was added and then the mixture was warmed to room temperature and stirred overnight. On the next day the mixture was concentrated. The residue was purified by column chromatography (dichloromethane) to give 52 mg of N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as off- white solid. Yield: 52%.

[0033] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.19 (m, 2H), 7.41 (m, 2H), 7.52 (m, 1H), 7.69-7.01 (m, 3H), 7.79 (d, J = 6.8 Hz, 1H), 7.92 (dd, J = 8.4, 1.2 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 8.34 (d, J = 8.4 Hz, 1H), 8.15 (s, 1H).

Step 5: 4-iodo-1H-indazol-3-amine

[0034] 500 mg of 2-fluoro-6-iodobenzonitrile and 1.3 ml of hydrazine hydrate (85%) were dissloved in 10 ml of n-butanol and heated to 110°C. The mixture was stirred for 6 hours and then cooled to room temperature. Water and ethyl acetate were added to separate. The aqueous phase was extracted with ethyl acetate. The combined organic phases was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give 502 mg of 4-iodo-1H-indazol-3-amine as tan solid. Yield: 96%.

[0035] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.05 (s, 2H), 6.90-6.96 (m, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.34 (d, J = 7.5 Hz, 1H), 11.80 (s, 1H).

Step 6: 6-(3-amino-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (1-1)

[0036] 30 mg of N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide, 17 mg of 4-iodo-1H-indazol-3-amine, 5 mg of palladium(II) bis(triphenyl phosphine) dichloride, 18 mg of sodium carbonate, 2 ml of ethanol, 1 ml of toluene and 1 ml of water were added to a reaction flask and heated under an argon atmosphere to 85 °C. The mixture was stirred for 2 h and then cooled to room temperature. Water and ethyl acetate were added to separate. The aqueous phase was extracted with ethyl acetate. The combined organic phases was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (methanol: dichloromethane = 3: 97) to give 14 mg of 1-1 as off-white solid. Yield: 56%.

[0037] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.95 (t, J = 3.6 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 7.34-7.37 (m, 2H), 7.39 (t, J = 8.0 Hz, 2H), 7.68 (dd, J = 8.4, 7.2 Hz, 1H), 7.75 (dd, J = 8.8, 2.0 Hz, 1H), 7.81 (dd, J = 7.2, 0.8 Hz, 1H), 7.84 (d, J = 8.0, 2H), 8.14 (d, J = 2.0 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.30 (d, J = 9.2 Hz, 1H), 10.64 (s, 1H), 11.84 (s, 1H).

Example 2:

6-(4-aminofuro[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalenecarboxamide (1-2)

[0038] 

Step 1: 3-bromofuro[3,2-c]pyridin-4-amine

[0039] 200 mg of 3-bromo-4-chlorofuro[3,2-c]pyridine, 3 ml of concentrated aqueous ammonia and 3 ml of dioxane were added to a stainless steel sealed tube, closed and heated to 150 °C. After stirred for 3 days, the mixture was cooled to room temperature. Water and ethyl acetate were added to separate. The aqueous phase was extracted with ethyl acetate. The combined organic phases was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give 98 mg of 3-bromofuro[3,2-c]pyridin-4-amine as tan solid. Yield: 67%.

[0040] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 6.19 (s, 2H), 6.92 (d, J = 6.0 Hz, 1H), 7.85 (d, J = 6.0 Hz, 1H), 8.11 (s, 1H).

Step 2: 6-(4-aminofuro[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalenecarboxamide (1-2)

[0041] 4-iodo-1H-indazol-3-amine was replaced by 3-bromofuro[3,2-c]pyridin-4-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1. I-2 as yellow solid was obtained.

[0042] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.68 (s, 2H), 7.02 (d, J = 6.0 Hz, 1H), 7.11-7.16 (m, 1H), 7.36-7.42 (m, 2H), 7.66-7.71 (m, 1H), 7.76 (dd, J = 9.0, 1.8 Hz, 1H), 7.82-7.85 (m, 3H), 7.92 (d, J = 6.0 Hz, 1H), 8.13-8.19 (m, 3H), 8.34 (d, J = 8.4 Hz, 1H), 10.62 (s, 1H).

Example 3:

6-(4-aminothieno[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalenecarboxamide (1-3)

[0043] 

[0044] 4-iodo-1H-indazol-3-amine was replaced by 3-bromothieno[3,2-c]pyridin-4-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1. 1-3 as yellow solid was obtained.

[0045] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.51 (s, 2H), 7.11-7.16 (m, 1H), 7.34-7.41 (m, 3H), 7.64 (s, 1H), 7.68-7.23 (m, 2H), 7.82-7.88 (m, 4H), 8.16-8.19 (m, 2H), 8.32 (d, J = 9.0 Hz, 1H), 10.64 (s, 1H).

Example 4:

6-(4-aminothieno[2,3-d]pyrimidin-5-yl)-N-phenyl-1-naphthalenecarboxamide (I-4)

[0046] 

Step 1: 5-bromothieno[2,3-d]pyrimidin-4-amine

[0047] 360 mg of 5-bromo-4-chlorothieno[2,3-d]pyrimidine and 20 ml of concentrated aqueous ammonia were added to a stainless steel sealed tube, closed and heated to 90 °C. After stirred for 24 h, the mixture was cooled to room temperature, filtered and washed with water to give 272 mg of 5-bromothieno[2,3-d]pyrimidin-4-amine as yellow solid. Yield: 82%.

[0048] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 6.99-7.65 (br s, 1H), 7.78 (s, 1H), 8.32 (s, 1H).

Step 2: 6-(4-aminothieno[2,3-d]pyrimidin-5-yl)-N-phenyl-1-naphthalenecarboxamide (I-4)

[0049] 4-iodo-1H-indazol-3-amine was replaced by 5-bromothieno[2,3-d]pyrimidin-4-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give I-4 as white solid.

[0050] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 7.14 (t, J = 7.2 Hz, 1H), 7.39-7.41 (m, 2H), 7.63 (s, 1H), 7.67-7.31 (m, 2H), 7.82-7.85 (m, 3H), 8.16-8.19 (m, 2H), 8.33 (d, J = 9.0 Hz, 1H), 8.38 (s, 1H), 10.62 (s, 1H).

Example 5:

6-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)-N-phenyl-1 -naphthalenecarboxamide (1-5)

[0051] 

Step 1: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-)ethanol

[0052] 100 mg of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 91 mg of 1,3-dioxolan-2-one were dissloved in 2 ml of dimethylformamide. 336 mg of cesium carbonate was heated to 140 °C, stirred for 0.5 h and then cooled to room temperature and concentrated. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 30: 70) to give 93 mg of 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethanol as pale yellow oil. Yield: 76%.

[0053] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 1.25 (s, 12H), 3.71 (q, J = 5.4 Hz, 2H), 4.15 (t, J = 5.4 Hz, 2H), 4.87 (t, J = 5.4 Hz, 1H), 7.57 (s, 1H), 7.88 (s, 1H).

Step 2: 6-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalenecarboxamide

[0054] 80 mg of 6-(4-aminothieno[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalenecarboxamide (1-3) was dissloved in 3 ml of dimethylformamide. In an ice bath, 50 mg of N-iodosuccinimide was added with stirring and stirred overnight. On the next day the mixture was concentrated. The residue was purified by column chromatography (methanol: dichloromethane = 2: 98) to give 94 mg of 6-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalenecarboxamide as black solid. Yield: 90%.

[0055] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.58 (s, 2H), 7.13 (t, J = 7.2 Hz, 1H), 7.39 (t, J = 7.8 Hz, 2H), 7.68-7.73 (m, 3H), 7.82-7.85 (m, 3H), 8.06 (s, 1H), 8.16-8.19 (m, 2H), 8.32 (d, J = 8.7 Hz, 1H), 10.64 (s, 1H).

Step 3: 6-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)-N-phenyl-1-nap hthalenecarboxamide (I-5)

[0056] 26 mg of 6-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthalene carboxamide, 24 mg of 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl) ethanol, 4 mg of palladium(II)bis(triphenylphosphine) dichloride, 13 mg of sodium carbonate, 2 ml of ethanol, 1 ml of toluene and 1 ml of water were added to a reaction flask and heated to 90 °C under Ar. After stirred for 4 h, the mixture was cooled to room temperature. Water and ethyl acetate were added to separate. The aqueous phase was extracted with ethyl acetate. The combined organic phases was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (methanol: dichloromethane = 5: 95) to give 8 mg of I-5 as brown solid. Yield: 32%.

[0057] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 3.81 (q, J = 5.2 Hz, 2H), 4.25 (t, J = 5.6 Hz, 2H), 5.02 (t, J = 5.2 Hz, 1H), 5.68 (s, 2H), 7.14 (t, J = 7.2 Hz, 1H), 7.39 (t, J = 8.0 Hz, 2H), 7.70-7.74 (m, 2H), 7.77 (s, 1H), 7.83-7.86 (m, 3H), 7.96 (s, 1H), 8.11 (s, 1H), 8.18-8.22 (m, 3H), 8.33 (d, J = 8.8 Hz, 1H), 10.67 (s, 1H).

Example 6:

6-(3-amino-1H-indazol-4-yl)-N-(o-methylphenyl)-1-naphthalenecarboxamide (1-6)

[0058] 

[0059] Step 1: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(o-methylphenyl)-1-naphthalenecarboxamid e

[0060] Phenylamine was replaced by o-methylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(o-methylphenyl)-1-naphthalenecarboxamid e as yellow solid.

[0061] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 2.32 (s, 3H), 7.14-7.17 (m, 1H), 7.25-7.26 (m, 1H), 7.31-7.35 (m, 1H), 7.51-7.55 (m, 2H), 7.83 (d, J = 6.4 Hz, 1H), 7.94 (dd, J = 8.4, 1.2 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 7.2 Hz, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.42 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(o-methylphenyl)-1-naphthalenecarboxamide (I-6)

[0062] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(o-methylphenyl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give I-6 as tan solid.

[0063] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 2.36 (s, 3H), 4.33 (s, 2H), 6.94-6.96 (m, 1H), 7.20-7.22 (m, 1H), 7.25-7.32 (m, 2H), 7.35-7.36 (m, 2H), 7.54 (d, J = 7.6 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.77 (dd, J = 8.8, 2.0 Hz, 1H), 7.88 (d, J = 7.2 Hz, 1H), 8.13 (d, J = 1.6 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.42 (d, J = 8.8 Hz, 1H), 10.12 (s, 1H), 11.84 (s, 1H).

Example 7:

6-(3-amino-1H-indazol-4-yl)-N-(m-methylphenyl)-1-naphthalenecarboxamide (1-7)

[0064] 

[0065] Step 1: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(m-methylphenyl)-1-naphthalenecarboxami de

[0066] Phenylamine was replaced by m-methylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(m-methylphenyl)-1-naphthalenecarboxamide as tan solid.

[0067] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 2.39 (s, 3H), 6.99 (d, J = 7.5 Hz, 1H), 7.27 (t, J = 8.1 Hz, 1H), 7.42-7.50 (m, 2H), 7.56 (s, 1H), 7.69-7.75 (m, 2H), 7.90 (dd, J = 8.4, 0.9 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 8.32 (d, J = 9.0 Hz, 1H), 8.40 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(m-methylphenyl)-1-naphthalenecarboxamide (I-7)

[0068] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(m-methylphenyl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give 1-7 as off-white solid.

[0069] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 2.34 (s, 3H), 4.32 (s, 2H), 6.93-6.97 (m, 2H), 7.26 (m, 1H), 7.34-7.35 (m, 2H), 7.60 (d, J = 8.0 Hz, 1H), 6.67 (t, J = 7.6 Hz, 1H), 7.71 (s, 1H), 7.75 (dd, J = 8.8, 1.6 Hz, 1H), 7.79 (d, J = 6.8 Hz, 1H), 8.13 (d, J = 1.2 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.29 (d, J = 8.8 Hz, 1H), 10.57 (s, 1H), 11.84 (s, 1H).

Example 8:

6-(3-amino-1H-indazol-4-yl)-N-(p-methylphenyl)-1-naphthalenecarboxamide (1-8)

[0070] 

Step 1: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(p-methylphenyl)-1-naphthalenecarboxamid e

[0071] Phenylamine was replaced by p-methylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(p-methylphenyl)-1-naphthalenecarboxamid e as yellow solid.

[0072] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 2.36 (s, 3H), 7.21 (d, J = 8.0 Hz, 2H), 7.49-7.53 (m, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.64 (s, 1H), 7.78 (d, J = 7.2 Hz, 1H), 7.92 (dd, J = 8.4, 0.8 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 8.34 (d, J = 8.4 Hz, 1H), 8.41 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(p-methylphenyl)-1-naphthalenecarboxamide (I-8)

[0073] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(p-methylphenyl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give I-8 as tan solid.

[0074] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 2.30 (s, 3H), 4.32 (s, 2H), 6.94 (t, J = 4.0 Hz, 1H), 7.19 (d, J = 8.0 Hz, 2H), 7.34-7.35 (m, 2H), 7.65-7.80 (m, 5H), 8.13 (s, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.30 (d, J = 8.8 Hz, 1H), 10.56 (s, 1H), 11.85 (s, 1H).

Example 9:

6-(3-amino-1H-indazol-4-yl)-N-(3-ethylphenyl)-1-naphthalenecarboxamide (1-9)

[0075] 

Step 1: N-(3-ethylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0076] Phenylamine was replaced by m-ethylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-ethylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as tan solid.

[0077] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.28 (t, J = 7.6 Hz, 3H), 1.40 (s, 12H), 2.69 (q, J = 7.6 Hz, 2H), 7.04 (d, J = 7.6 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.49-7.53 (m, 2H), 7.57 (s, 1H), 7.65 (s, 1H), 7.78 (d, J = 6.8 Hz, 1H), 7.92 (dd, J = 8.4, 1.2 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 8.35 (d, J = 8.4 Hz, 1H), 8.42 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-ethylphenyl)-1-naphthalenecarboxamide (1-9)

[0078] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-ethylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give 1-9 as white solid.

[0079] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 1.21 (t, J = 7.6 Hz, 3H), 2.63 (q, J = 7.6, 2H), 4.32 (s, 2H), 6.94 (t, J = 4.0 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 7.27-7.31 (m, 1H), 7.33-7.36 (m, 2H), 7.62-7.69 (m, 2H), 7.73-7.80 (m, 3H), 8.13 (d, J = 1.2 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.30 (d, J = 8.4 Hz, 1H), 10.58 (s, 1H), 11.84 (s, 1H).

Example 10:

6-(3-amino-1H-indazol-4-yl)-N-(2-fluorophenyl)-1-naphthalenecarboxamide (1-10)

[0080] 

Step 1: N-(2-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0081] Phenylamine was replaced by 2-fluorophenylamineand other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(2-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as yellow solid.

[0082] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.12-7.16 (m, 2H), 7.24-7.26 (m, 1H), 7.53 (dd, J = 8.4, 7.2 Hz, 1H), 7.82 (dd, J = 7.2, 0.8 Hz, 1H), 7.93-7.95 (m, 2H), 8.04 (d, J = 8.0 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.43 (s, 1H), 8.59 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(2-fluorophenyl)-1-naphthalenecarboxamide (I-10)

[0083] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(2-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid 1-10.

[0084] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.95 (t, J = 4.0 Hz, 1H), 7.27-7.36 (m, 5H), 6.68 (t, J = 7.6 Hz, 1H), 7.76 (dd, J = 8.8, 2.0 Hz, 1H), 7.81-7.86 (m, 2H), 8.13 (d, J = 1.6 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.38 (d, J = 8.8 Hz, 1H), 10.43 (s, 1H), 11.84 (s, 1H).

Example 11:

6-(3-amino-1H-indazol-4-yl)-N-(3-fluorophenyl)-1-naphthalenecarboxamide (1-11)

[0085] 

Step 1: N-(3-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0086] Phenylamine was replaced by 3-fluorophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as faint yellow solid.

[0087] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 6.87-6.91 (m, 1H), 7.29-7.35 (m, 2H), 7.50-7.54 (m, 1H), 7.69-7.72 (m, 1H), 7.75-7.79 (m, 2H), 7.93 (d, J = 8.8 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 8.31 (d, J = 8.8 Hz, 1H), 8.42 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-fluorophenyl)-1-naphthalenecarboxamide (I-11)

[0088] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid I-11.

[0089] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.94-7.00 (m, 2H), 7.35-7.36 (m, 2H), 7.40-7.45 (m, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.67-7.71 (m, 1H), 7.76 (dd, J = 8.8, 2.0 Hz, 1H), 7.82-7.86 (m, 2H), 8.14 (d, J = 1.6 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.30 (d, J = 8.8 Hz, 1H), 10.86 (s, 1H), 11.85 (s, 1H).

Example 12:

6-(3-amino-1H-indazol-4-yl)-N-(4-fluorophenyl)-1-naphthalenecarboxamide (1-12)

[0090] 

Step 1: N-(4-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0091] Phenylamine was replaced by 4-fluorophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(4-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as off-white solid.

[0092] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.10 (t, J = 8.4 Hz, 2H), 7.50-7.54 (m, 1H), 7.64-7.69 (m, 3H), 7.78 (d, J = 6.4 Hz, 1H), 7.93 (dd, J = 8.4, 1.2 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.42 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(4-fluorophenyl)-1-naphthalenecarboxamide (I-12)

[0093] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(4-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid I-12.

[0094] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.31 (s, 2H), 6.93-6.96 (m, 1H), 7.24 (t, J = 9.0 Hz, 2H), 7.34-7.36 (m, 2H), 7.65-7.70 (m, 1H), 7.75 (dd, J = 8.7, 1.8 Hz, 1H), 7.80-7.88 (m, 3H), 8.13 (d, J = 1.5 Hz, 1H), 8.18 (d, J = 8.1 Hz, 1H), 8.31 (d, J = 9.0 Hz, 1H), 10.68 (s, 1H), 11.83 (s, 1H).

Example 13:

6-(3-amino-1H-indazol-4-yl)-N-(2,4-difluorohenl)-1-nahthalenecarboxamide (1-13)

[0095] 

Step 1: N-(2,4-difluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxa mide

[0096] Phenylamine was replaced by 2,4-difluorophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(2,4-difluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxa mide as yellow solid.

[0097] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 6.92-7.03 (m, 2H), 7.54-7.57 (m, 1H), 7.83-7.84 (m, 2H), 7.96 (dd, J = 8.4, 1.2 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.44 (s, 1H), 8.55-8.58 (m, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(2,4-difluorophenyl)-1-naphthalenecarboxamide (I-13)

[0098] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(2,4-difluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-13.

[0099] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.95 (t, J = 4.0 Hz, 1H), 7.18-7.22 (m, 1H), 7.35-7.36 (m, 2H), 7.39-7.44 (m, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.75-7.80 (m, 2H), 7.85 (d, J = 6.8 Hz, 1H), 8.13 (d, J = 1.6 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1H), 8.38 (d, J = 8.8 Hz, 1H), 10.44 (s, 1H), 11.85 (s, 1H).

[0100] Example 14:

6-(3-amino-1H-indazol-4-yl)-N-(3,5-difluorophenyl)-1-naphthalenecarboxamide (I-14)

[0101] 

Step 1: N-(3,5-difluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxa mide

[0102] Phenylamine was replaced by 3,5-difluorophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3,5-difluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxa mide as off-white solid.

[0103] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 6.61-6.66 (m, 1H), 7.31 (d, J = 7.2 Hz, 2H), 7.49-7.53 (m, 1H), 7.75-7.77 (m, 2H), 7.94 (d, J = 8.8 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.42 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3,5-difluorophenyl)-1-naphthalenecarboxamide (I-14)

[0104] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3,5-difluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give faint yellow solid I-14.

[0105] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.95-7.02 (m, 2H), 7.35 (s, 2H), 7.57-7.59 (s, 2H), 7.69-7.85 (m, 3H), 8.15-8.31 (m, 3H), 11.02 (s, 1H), 11.85 (s, 1H).

Example 15:

6-(3-amino-1H-indazol-4-yl)-N-(3-chlorophenyl)-1-naphthalenecarboxamide (I-15)

[0106] 

Step 1: N-(3-chlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamid e

[0107] Phenylamine was replaced by 3-chlorophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-chlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamid e as faint yellow solid.

[0108] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.16 (d, J = 8.4 Hz, 1H), 7.30-7.34 (m, 1H), 7.50-7.54 (m, 2H), 7.70 (s, 1H), 7.77 (d, J = 6.8 Hz, 1H), 7.86 (s, 1H), 7.93 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 8.4 Hz, 1H), 8.42 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-chlorophenyl)-1-naphthalenecarboxamide (I-15)

[0109] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-chlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid 1-15.

[0110] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.33 (s, 2H), 6.94 (t, J = 4.0 Hz, 1H), 7.19-7.22 (m, 1H), 7.34-7.35 (m, 2H), 7.42 (t, J = 8.0 Hz, 1H), 7.67-7.73 (m, 2H), 7.75 (dd, J = 8.8, 2.0 Hz, 1H), 7.83 (dd, J = 6.8, 0.8 Hz, 1H), 8.06 (t, J = 2.0 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.30 (d, J = 8.4 Hz, 1H), 10.83 (s, 1H), 11.85 (s, 1H).

Example 16:

6-(3-amino-1H-indazol-4-yl)-N-(3-bromophenyl)-1-naphthalenecarboxamide (I-16)

[0111] 

Step 1: N-(3-bromophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamid e

[0112] Phenylamine was replaced by 3-bromophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-bromophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamid e as faint yellow solid.

[0113] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.28 (m, 1H), 7.31-7.33 (m, 1H), 7.50-7.58 (m, 2H), 7.68 (s, 1H), 7.77 (d, J = 6.8 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.80-8.04 (m, 2H), 8.31 (d, J = 8.4 Hz, 1H), 8.42 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-bromophenyl)-1-naphthalenecarboxamide (I-16)

[0114] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-bromophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid 1-16.

[0115] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.94 (t, J = 4.0 Hz, 1H), 7.32-7.38 (m, 4H), 7.66-7.70 (m, 1H), 7.74-7.76 (m, 2H), 7.83 (dd, J = 6.8, 0.8 Hz, 1H), 8.14 (d, J = 1.2 Hz, 1H), 8.19-8.21 (m, 2H), 8.30 (d, J = 8.8 Hz, 1H), 10.82 (s, 1H), 11.85 (s, 1H).

Example 17:

6-(3-amino-1H-indazol-4-yl)-N-(3,5-dichlorophenyl)-1-naphthalenecarboxamide (1-17)

[0116] 

Step 1: N-(3,5-dichlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxa mide

[0117] Phenylamine was replaced by 3,5-dichlorophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3,5-dichlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxa mide as white solid.

[0118] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.18 (m, 1H), 7.49-7.54 (m, 1H), 7.67-7.76 (m, 4H), 7.93 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 8.7 Hz, 1H), 8.29 (d, J = 9.0 Hz, 1H), 8.41 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3,5-dichlorophenyl)-1-naphthalenecarboxamide (I-17)

[0119] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3,5-dichlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid 1-17 .

[0120] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.95 (t, J = 4.0 Hz, 1H), 7.35-7.36 (m, 2H), 7.39 (t, J = 2.0 Hz, 1H), 7.70 (dd, J = 8.0, 7.2 Hz, 1H), 7.76 (dd, J = 8.8, 2.0 Hz, 1H), 7.85 (dd, J = 7.2, 1.2 Hz, 1H), 7.93-7.94 (m, 2H), 8.15 (d, J = 1.6 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 8.4 Hz, 1H), 10.99 (s, 1H), 11.85 (s, 1H).

Example 18:

6-(3-amino-1H-indazol-4-yl)-N-(3,5-dibromophenyl)-1-naphthalenecarboxamide (1-18)

[0121] 

Step 1: N-(3,5-dibromophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxa mide

[0122] Phenylamine was replaced by 3,5-dibromophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3,5-dibromophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxa mide as off-white solid.

[0123] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.48 (s, 1H), 7.49-7.53 (m, 1H), 7.71 (s, 1H), 7.75 (d, J = 7.2 Hz, 1H), 7.87 (s, 2H), 7.94 (d, J = 8.8 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.40 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3,5-dibromophenyl)-1-naphthalenecarboxamide (I-18)

[0124] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3,5-dibromophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid 1-18.

[0125] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.94 (m, 1H), 7.34-7.35 (m, 2H), 7.61 (s, 1H), 7.67-7.71 (m, 1H), 7.75-7.77 (m, 1H), 7.84 (d, J = 6.8 Hz, 1H), 8.11-8.15 (m, 3H), 8.22 (d, J = 8.0 Hz, 1H), 8.31 (d, J = 8.4 Hz, 1H), 10.94 (s, 1H), 11.84 (s, 1H).

Example 19:

6-(3-amino-1H-indazol-4-yl)-N-(3-(trifluoromethyl)phenyl)-1-naphthalenecarboxamide (I-19)

[0126] 

Step 1: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(3-(trifluoromethyl)phenyl)-1-naphthalenec arboxamide

[0127] Phenylamine was replaced by 3-trifluoromethylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(3-(trifluoromethyl)phenyl)-1-naphthalenec arboxamide as yellow solid.

[0128] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.44 (d, J = 7.6 Hz, 1H), 7.49-7.54 (m, 2H), 7.78 (d, J = 7.2 Hz, 1H), 7.85 (s, 1H), 7.89-7.94 (m, 2H), 8.00-8.04 (m, 2H), 8.32 (d, J = 8.8 Hz, 1H), 8.41 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-(trifluoromethyl)phenyl)-1-naphthalenecarboxamide (I-19)

[0129] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(3-(trifluoromethyl)phenyl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid I-19.

[0130] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.95 (t, J = 4.0 Hz, 1H), 7.34-7.35 (m, 2H), 7.50 (d, J = 7.6 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.67-7.71 (m, 1H), 7.75 (dd, J = 8.8, 2.0 Hz, 1H), 7.86 (dd, J = 7.2, 1.2 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H), 8.21 (d, J = 8.4 Hz, 1H), 8.33 (d, J = 8.8 Hz, 1H), 8.37 (s, 1H), 10.99 (s, 1H), 11.85 (s, 1H).

Example 20:

6-(3-amino-1H-indazol-4-yl)-N-(2-fluoro-5-methylphenyl)-1-naphthalenecarboxamide (I-20)

[0131] 

Step 1: N-(2-fluoro-5-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecar boxamide

[0132] Phenylamine was replaced by 2-fluoro-5-methylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(2-fluoro-5-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecar boxamide as tan solid.

[0133] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 2.41 (s, 3H), 6.91-6.93 (m, 1H), 7.00-7.04 (m, 1H), 7.51-7.55 (m, 1H), 7.81 (d, J = 6.4 Hz, 1H), 7.87 (m, 1H), 7.94 (dd, J = 8.4, 1.2 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.41-8.42 (m, 2H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(2-fluoro-5-methylphenyl)-1-naphthalenecarboxamide (I-20)

[0134] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(2-fluoro-5-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid I-20.

[0135] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 2.34 (s, 3H), 4.32 (s, 2H), 6.95 (t, J = 4.0 Hz, 1H), 7.08-7.10 (m, 1H), 7.18-7.23 (m, 1H), 7.35-7.37 (m, 2H), 7.62 (d, J = 6.4 Hz, 1H), 7.65-7.69 (m, 1H), 7.76 (dd, J = 8.8, 2.0 Hz, 1H), 7.82 (d, J = 6.8 Hz, 1H), 8.13 (d, J = 1.6 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 10.37 (s, 1H), 11.86 (s, 1H).

Example 21:

6-(3-amino-1H-indazol-4-yl)-N-(4-fluoro-3-methylphenyl)-1-naphthalenecarboxamide (I-21)

[0136] 

Step 1: N-(4-fluoro-3-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecar boxamide

[0137] Phenylamine was replaced by 4-fluoro-3-methylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(4-fluoro-3-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecar boxamide as off-white solid.

[0138] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 2.32 (d, J = 0.6 Hz, 3H), 7.02 (t, J = 9.0 Hz, 1H), 7.39-7.42 (m, 1H), 7.48-7.53 (m, 1H), 7.57-7.62 (m, 2H), 7.76 (d, J = 7.2 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.41 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(4-fluoro-3-methylphenyl)-1-naphthalenecarboxamide (I-21)

[0139] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(4-fluoro-3-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid I-21.

[0140] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 2.27 (s, 3H), 4.32 (s, 2H), 6.94 (t, J = 3.6 Hz, 1H), 7.16 (t, J = 9.2 Hz, 1H), 7.34-7.35 (m, 2H), 7.61-7.69 (m, 2H), 7.73-7.80 (m, 3H), 8.13 (s, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.29 (d, J = 8.4 Hz, 1H), 10.62 (s, 1H), 11.84 (s, 1H).

Example 22:

6-(3-amino-1H-indazol-4-yl)-N-(2-fluoro-4-methylphenyl)-1-naphthalenecarboxamide (I-22)

[0141] 

Step 1: N-(2-fluoro-4-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecar boxamide

[0142] Phenylamine was replaced by 2-fluoro-4-methylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(2 fluoro-4-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecar boxamide as off-white solid.

[0143] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 2.63 (s, 3H), 6.94-7.05 (m, 2H), 7.50-7.55 (m, 1H), 7.78-7.82 (m, 2H), 7.93 (d, J = 8.4 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 8.36-8.44 (m, 3H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(2-fluoro-4-methylphenyl)-1-naphthalenecarboxamide (I-22)

[0144] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(2-fluoro-4-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-22.

[0145] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 2.35 (s, 3H), 4.32 (s, 2H), 6.94 (t, J = 4.0 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 11.6 Hz, 1H), 7.34-7.35 (m, 2H), 7.64-7.69 (m, 2H), 7.75 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 6.8 Hz, 1H), 8.12 (s, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 10.32 (s, 1H), 11.85 (s, 1H).

Example 23:

6-(3-amino-1H-indazol-4-yl)-N-(3-fluoro-4-methylphenyl)-1-naphthalenecarboxamide (I-23)

[0146] 

Step 1: N-(3-fluoro-4-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecar boxamide

[0147] Phenylamine was replaced by 3-fluoro-4-methylphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-fluoro-4-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecar boxamide as off-white solid.

[0148] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 2.27 (d, J = 1.8 Hz, 3H), 7.17-7.18 (m, 2H), 7.48-7.53 (m, 1H), 7.61-7.66 (m, 2H), 7.76 (d, J = 7.2 Hz, 1H), 7.92 (dd, J = 8.7, 1.5 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 8.32 (d, J = 8.7 Hz, 1H), 8.41 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-fluoro-4-methylphenyl)-1-naphthalenecarboxamide (I-23)

[0149] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-fluoro-4-methylphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-23.

[0150] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 2.23 (s, 3H), 4.32 (s, 2H), 6.94 (t, J = 4.0 Hz, 1H), 7.28 (t, J = 8.4 Hz, 1H), 7.34-7.35 (m, 2H), 7.46-7.48 (m, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.74-7.81 (m, 3H), 8.13 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.29 (d, J = 8.8 Hz, 1H), 10.75 (s, 1H), 11.85 (s, 1H).

Example 24:

6-(3-amino-1H-indazol-4-yl)-N-(5-methylisoxazol-3-yl)-1-naphthalenecarboxamide (I-24)

[0151] 

Step 1: N-(5-methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarbo xamide

[0152] Phenylamine was replaced by 5-methylisoxazolamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(5-methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarbo xamide as white solid.

[0153] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 2.47 (s, 3H), 6.95 (s, 1H), 7.50-7.54 (m, 1H), 7.82 (dd, J = 7.2, 1.2 Hz, 1H), 7.94 (dd, J = 8.4, 1.2 Hz, 1H), 8.05 (d, J = 8.0, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.42 (s, 1H), 8.50 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(5-methylisoxazol-3-yl)-1-naphthalenecarboxamide (1-24)

[0154] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(5-methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-24.

[0155] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 2.46 (s, 3H), 4.32 (s, 2H), 6.87 (s, 1H), 6.95 (t, J = 3.6 Hz, 1H), 7.35-7.36 (m, 2H), 7.66 (dd, J = 8.0, 7.2 Hz, 1H), 7.76 (dd, J = 8.4, 1.6 Hz, 1H), 7.84 (dd, J = 7.2, 0.8 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 8.8 Hz, 1H), 11.58 (s, 1H), 11.85 (s, 1H).

Example 25:

6-(3-amino-1H-indazol-4-yl)-N-(pyridin-3-yl)-1-naphthalenecarboxamide (1-25)

[0156] 

Step 1: N-(pyridin-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0157] Phenylamine was replaced by 3-aminopyridine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(pyridin-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as white solid.

[0158] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.35-7.39 (m, 1H), 7.51-7.56 (m, 1H), 7.75 (s, 1H), 7.80-7.82 (m, 1H), 7.94 (dd, J = 8.4, 1.2 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.40-8.44 (m, 3H), 8.67 (d, J = 2.1 Hz, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(pyridin-3-yl)-1-naphthalenecarboxamide (I-25)

[0159] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(pyridin-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give faint yellow solid I-25.

[0160] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 4.32 (s, 2H), 6.95 (t, J = 4.0 Hz, 1H), 7.35-7.36 (m, 2H), 7.43-7.47 (m, 1H), 7.68-7.72 (m, 1H), 7.76 (dd, J = 8.8, 2.0 Hz, 1H), 7.87 (dd, J = 7.2, 0.8 Hz, 1H), 8.15 (d, J = 1.6 Hz, 1H), 8.21 (d, J = 8.4 Hz, 1H), 8.28-8.30 (m, 1H), 8.33-8.36 (m, 2H), 8.98 (d, J = 2.4 Hz, 1H), 10.87 (s, 1H), 11.85 (s, 1H).

Example 26:

6-(3-amino-1H-indazol-4-yl)-N-ethyl-1-naphthalenecarboxamide (I-26)

[0161] 

Step 1: N-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0162] Phenylamine was replaced by ethylamine (2 mol/L, in tetrahydrofuran) and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as white solid.

[0163] ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.31 (t, J = 7.2 Hz, 3H), 1.40 (s, 12H), 3.56-3.63 (m, 2H), 5.96 (m, 1H), 7.45 (dd, J = 8.4, 7.2 Hz, 1H), 7.63 (dd, J = 7.2, 1.2 Hz, 1H), 7.90 (dd, J = 8.4, 1.2 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 8.26 (d, J = 8.8 Hz, 1H), 8.38 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-ethyl-1-naphthalenecarboxamide (1-26)

[0164] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-)-1-naphthalenecarboxamide was replaced by N-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid 1-26.

[0165] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 1.20 (t, J = 7.2 Hz, 3H), 3.40 (m, 2H), 4.30 (s, 2H), 6.92-6.94 (m, 1H), 7.34-7.35 (m, 2H), 7.58-7.64 (m, 2H), 7.71 (dd, J = 8.8, 2.0 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 8.10 (dd, J = 8.0, 2.0 Hz, 1H), 8.31 (d, J = 8.8 Hz, 1H), 8.60 (t, J = 5.6 Hz, 1H), 11.83 (s, 1H).

Example 27:

6-(3-amino-1H-indazol-4-yl)-N-cyclopropyl-1-naphthalenecarboxamide (I-27)

[0166] 

Step 1: N-cyclopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0167] Phenylamine was replaced by cyclopropylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-cyclopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as white solid.

[0168] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 0.67-0.70 (m, 2H), 0.90-0.94 (m, 2H), 1.39 (s, 12H), 3.01-3.04 (m, 1H), 6.08 (s, 1H), 7.41-7.46 (m, 1H), 7.59-7.61 (m, 1H), 7.89-7.96 (m, 2H), 8.26 (d, J = 8.4 Hz, 1H), 8.37 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-cyclopropyl-1-naphthalenecarboxamide (I-27)

[0169] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-cyclopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give off-white solid I-27.

[0170] ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 0.61-0.63 (m, 2H), 0.74-0.76 (m, 2H), 2.97 (m, 1H), 4.30 (s, 2H), 6.93 (t, J = 4.0 Hz, 1H), 7.34-7.35 (m, 2H), 7.58-7.60 (m, 2H), 7.71 (dd, J = 8.8, 2.0 Hz, 1H), 8.07 (d, J = 1.6 Hz, 1H), 8.09 (dd, J = 6.4, 2.4 Hz, 1H), 8.30 (d, J = 8.4 Hz, 1H), 8.64 (d, J = 4.4 Hz, 1H), 11.84 (s, 1H).

Example 28:

6-(3-amino-1H-indazol-4-yl)-5-fluoro-N-phenyl-1-naphthalenecarboxamide (1-28)

[0171] 

Step 1: methyl 5-fluoro-6-hydroxy-1-naphthoate

[0172] 1 g of methyl 6-hydroxy-1-naphthoate was dissloved in 10 ml of acetonitrile and 1.92 g of 1-chloromethyl-4-fluoro-1,4-diazabicyclo[2.2.2]octane bis(tetrafluoroborate) was added and heated to 85 °C. After stirred for 24 h, the mixture was cooled to room temperature and then concentrated. The residue was purified by column chromatography (dichloromethane) to give 593 mg of methyl 5-fluoro-6-hydroxy-1-naphthoate as yellow solid. Yield: 54%.

[0173] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 3.92 (s, 3H), 7.40 (t, J = 9.0 Hz, 1H), 7.59-7.64 (m, 1H), 7.98 (d, J = 7.2 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 8.43 (d, J = 9.3 Hz, 1H), 10.34 (s, 1H).

Step 2: methyl 5-fluoro-6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate

[0174] Methyl 6-hydroxy-1-naphthoate was replaced by methyl 5-fluoro-6-hydroxy-1-naphthoate and other raw materials, reagents and preparation method were identical with those in step 1 of example 1 to give methyl 5-fluoro-6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate as pale yellow oil.

[0175] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 3.98 (s, 3H), 7.86-7.97 (m, 2H), 8.36 (dd, J = 7.2, 0.9 Hz, 1H), 8.47 (d, J = 8.4 Hz, 1H), 8.75 (dd, J = 9.6, 0.6 Hz, 1H).

Step 3: methyl 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate

[0176] Methyl 6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate was replaced by methyl 5-fluoro-6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate and other raw materials, reagents and preparation method were identical with those in step 2 of example 1 to give methyl 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate as white solid.

[0177] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.41 (s, 12H), 4.01 (s, 3H), 7.56 (dd, J = 8.4, 7.8 Hz, 1H), 7.84 (dd, J = 8.4, 6.0 Hz, 1H), 8.27 (dd, J = 7.5, 1.2 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.66 (dd, J = 8.7, 0.9 Hz, 1H).

Step 4: 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid

[0178] Methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate was replaced by methyl 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate and other raw materials, reagents and preparation method were identical with those in step 3 of example 1 to give 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid as white solid.

[0179] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 1.35 (s, 12H), 7.70-7.78 (m, 2H), 8.28 (dd, J = 7.5, 1.2 Hz, 1H), 8.34 (d, J = 8.1 Hz, 1H), 8.66 (d, J = 9.0 Hz, 1H).

Step 5: 5-fluoro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0180] 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid was replaced by 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acidand other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give 5-fluoro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide as yellow solid.

[0181] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.41 (s, 12H), 7.20 (t, J = 7.2 Hz, 1H), 7.41 (t, J = 7.8 Hz, 2H), 7.53-7.58 (m, 1H), 7.68-7.72 (m, 3H), 7.77-7.83 (m, 2H), 8.09 (d, J = 8.4 Hz, 1H), 8.29 (d, J = 8.4 Hz, 1H).

Step 6: 6-(3-amino-1H-indazol-4-yl)-5-fluoro-N-phenyl-1-naphthalenecarboxamide (1-28)

[0182] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by 5-fluoro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give brown solid 1-28.

[0183] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.19 (s, 2H), 6.94 (dd, J = 5.7, 2.1 Hz, 1H), 7.12-7.17 (m, 1H), 7.33-7.42 (m, 4H), 7.61-7.66 (m, 1H), 7.77-7.84 (m, 3H), 7.90-7.92 (m, 1H), 8.12 (d, J = 8.7 Hz, 1H), 8.29 (d, J = 8.4 Hz, 1H), 10.69 (s, 1H), 11.88 (s, 1H).

Example 29:

6-(3-amino-1-methyl-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-29)

[0184] 

Step 1: 4-iodo-1-methyl-1H-indazol-3-amine

[0185] Hydrazine hydrate was replaced by methylhydrazine and other raw materials, reagents and preparation method were identical with those in step 5 of example 1 to give 4-iodo-1-methyl-1H-indazol-3-amine as yellow solid.

[0186] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 3.74 (s, 3H), 5.12 (s, 2H), 6.97 (dd, J = 8.4, 7.5 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H).

Step 2: 6-(3-amino-1-methyl-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-29)

[0187] 4-iodo-1H-indazol-3-amine was replaced by 4-iodo-1-methyl-1H-indazol-3-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give yellow solid I-29.

[0188] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 3.83 (s, 3H), 4.38 (s, 2H), 6.96 (d, J = 6.9 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.37-7.47 (m, 4H), 7.68-7.75 (m, 2H), 7.80-7.85 (m, 3H), 8.13 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 8.7 Hz, 1H), 10.64 (s, 1H).

Example 30:

6-(3-amino-1H-indazol-4-yl)-N-phenyl-2-naphthalenecarboxamide (I-30)

[0189] 

Step 1: methyl 6-(trifluoromethylsulfonyloxy)-2-naphthoate

[0190] 6-hydroxy-1-naphthoic acid was replaced by 6-hydroxy-2-naphthoic acid and other raw materials, reagents and preparation method were identical with those in step 1 of example 1 to give methyl 6-(trifluoromethylsulfonyloxy)-2-naphthoate as yellow solid.

[0191] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 4.01 (s, 3H), 7.45 (dd, J = 9.0, 2.4 Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 8.4 Hz, 1H), 8.06 (d, J = 9.3 Hz, 1H), 8.17 (dd, J = 8.4, 1.2 Hz, 1H), 8.66 (s, 1H).

Step 2: methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate

[0192] Methyl 6-(trifluoromethylsulfonyloxy)-1-naphthoate was replaced by methyl 6-(trifluoromethylsulfonyloxy)-2-naphthoate and other raw materials, reagents and preparation method were identical with those in step 2 of example 1 to give methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate as white solid.

[0193] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 3.98 (s, 3H), 7.88-7.95 (m, 3H), 8.06 (d, J = 8.4 Hz, 1H), 8.40 (s, 1H), 8.60 (s, 1H).

Step 3: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoic acid

[0194] Methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate was replaced by methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate and other raw materials, reagents and preparation method were identical with those in step 3 of example 1 to give 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoic acid as white solid.

[0195] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 1.34 (s, 12H), 7.78 (d, J = 8.1 Hz, 1H), 7.98 (dd, J = 8.7, 1.5 Hz, 1H), 8.08-8.13 (m, 2H), 8.38 (s, 1H), 8.60 (s, 1H), 13.15 (s, 1H).

Step 4: N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthalenecarboxamide

[0196] 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid was replaced by 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoic acidand other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthalenecarboxamide as orange jelly.

[0197] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.41 (s, 12H), 7.16-7.26 (m, 1H), 7.41 (t, J = 7.8 Hz, 2H), 7.70 (d, J = 8.1 Hz, 2H), 7.91-8.01 (m, 5H), 8.37 (s, 1H), 8.42 (s, 1H).

Step 5: 6-(3-amino-1H-indazol-4-yl)-N-phenyl-2-naphthalenecarboxamide (I-30)

[0198] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give yellow solid I-30.

[0199] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.33 (s, 2H), 6.96-6.98 (m, 1H), 7.13 (t, J = 7.5 Hz, 1H), 7.35-7.42 (m, 4H), 7.76 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 7.5 Hz, 2H), 8.07-8.17 (m, 3H), 8.22 (d, J = 8.4 Hz, 1H), 8.67 (s, 1H), 10.48 (s, 1H), 11.86 (s, 1H).

Example 31:

6-(3-amino-1H-indazol-4-yl)-5-fluoro-N-phenyl-2-naphthalenecarboxamide (I-31)

[0200] 

Step 1: methyl 5-fluoro-6-hydroxy-2-naphthoate

[0201] Methyl 6-hydroxy-1-naphthoate was replaced by methyl 6-hydroxy-2-naphthoate and other raw materials, reagents and preparation method were identical with those in step 1 of example 28 to give methyl 5-fluoro-6-hydroxy-2-naphthoate as yellow solid.

[0202] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 3.90 (s, 3H), 7.35 (t, J = 8.7 Hz, 1H), 7.87 (d, J = 9.0 Hz, 1H), 7.94-7.98 (m, 2H), 8.58 (s, 1H), 10.58 (s, 1H).

Step 2: methyl 5-fluoro-6-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate

[0203] Methyl 6-hydroxy-1-naphthoate was replaced by methyl 5-fluoro-6-hydroxy-2-naphthoate and other raw materials, reagents and preparation method were identical with those in step 1 of example 1 to give methyl 5-fluoro-6-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate as yellow solid.

[0204] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 4.02 (s, 3H), 7.48 (dd, J = 9.0, 6.9 Hz, 1H), 7.84 (dd, J = 9.0, 1.5 Hz, 1H), 8.19-8.26 (m, 2H), 8.66 (s, 1H).

Step 3: methyl 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate

[0205] Methyl 6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate was replaced by methyl 5-fluoro-6-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate and other raw materials, reagents and preparation method were identical with those in step 2 of example 1 to give methyl 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate as yellow solid.

Step 4: 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoic acid

[0206] Methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate was replaced by methyl 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate and other raw materials, reagents and preparation method were identical with those in step 3 of example 1 to give 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoic acid as white solid.

Step 5: 5-fluoro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthalenecarboxamide

[0207] 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid was replaced by 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoic acidand other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give 5-fluoro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthalene carboxamide as yellow solid.

Step 6: 6-(3-amino-1H-indazol-4-yl)-5-fluoro-N-phenyl-2-naphthalenecarboxamide (I-31)

[0208] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by 5-fluoro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give brown solid I-31.

[0209] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.21 (s, 2H), 6.96 (d, J = 6.0 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.36-7.43 (m, 4H), 7.64 (t, J = 8.1 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 8.07 (d, J = 8.4 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.26 (d, J = 9.0 Hz, 1H), 8.74 (s, 1H), 10.55 (s, 1H), 11.85 (s, 1H).

Example 32:

6-(3-amino-1H-indazol-4-yl)-5-chloro-N-phenyl-1-naphthalenecarboxamide (I-32)

[0210] 

Step 1: methyl 5-chloro-6-hydroxy-1-naphthoate

[0211] 1 g of methyl 6-hydroxy-1-naphthoate and 762 mg of N-chlorosuccinimide were dissloved in 100 ml of tetrahydrofuran and stirred at room temperature for 5h, then concentrated. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 10: 90) to give 1.17 g of methyl 5-chloro-6-hydroxy-1-naphthoate as white solid. Yield: 100%.

[0212] ¹H NMR (300 MHz, DMSO-d6) δ (ppm): 3.93 (s, 3H), 7.43 (d, J = 9.3 Hz, 1H), 7.67 (dd, J = 8.1, 7.2 Hz, 1H), 7.96 (d, J = 7.5 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.57 (d, J = 9.3 Hz, 1H), 10.73 (s, 1H).

Step 2: methyl 5-chloro-6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate

[0213] Methyl 6-hydroxy-1-naphthoate was replaced by methyl 5-chloro-6-hydroxy-1-naphthoate and other raw materials, reagents and preparation method were identical with those in step 1 of example 1 to give methyl 5-chloro-6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate as faint yellow solid.

[0214] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 4.03 (s, 3H), 7.56 (d, J = 9.6 Hz, 1H), 7.71-7.77 (m, 1H), 8.33 (dd, J = 7.2, 0.9 Hz, 1H), 8.58 (d, J = 8.4 Hz, 1H), 9.05 (d, J = 9.0 Hz, 1H).

Step 3: methyl 5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate

[0215] Methyl 6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate was replaced by methyl 5-chloro-6-(((trifluoromethyl)sulfonyl)oxy)-1-naphthoate and other raw materials, reagents and preparation method were identical with those in step 2 of example 1 to give methyl 5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate as yellow solid.

[0216] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.43 (s, 12H), 4.00 (s, 3H), 7.60 (t, J = 8.1 Hz, 1H), 7.79 (d, J = 9.0 Hz, 1H), 8.23 (d, J = 7.2 Hz, 1H), 8.66 (d, J = 8.4 Hz, 1H), 8.80 (d, J = 8.7 Hz, 1H).

Step 4: 5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid

[0217] Methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate was replaced by methyl 5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate and other raw materials, reagents and preparation method were identical with those in step 3 of example 1 to give 5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid as yellow solid.

Step 5: 5-chloro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0218] 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid was replaced by 5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoic acid and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give 5-chloro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide as yellow solid.

Step 6: 6-(3-amino-1H-indazol-4-yl)-5-fluoro-N-phenyl-1-naphthalenecarboxamide (I-32)

[0219] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by 5-chloro-N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalene carboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give brown solid I-32.

[0220] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.01 (s, 2H), 6.84-6.86 (m, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.35-7.42 (m, 4H), 7.63 (d, J = 8.7 Hz, 1H), 7.82-7.89 (m, 3H), 7.92-7.94 (m, 1H), 8.25 (d, J = 7.8 Hz, 1H), 8.49 (d, J = 8.1 Hz, 1H), 10.72 (s, 1H), 11.80 (s, 1H).

Example 33:

6-(3-amino-7-fluoro-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (1-33)

[0221] 

Step 1: 7-fluoro-4-iodo-1H-indazol-3-amine

[0222] 2-fluoro-6-iodobenzonitrile was replaced by 2,3-difluoro-6-iodobenzonitrile and other raw materials, reagents and preparation method were identical with those in step 5 of example 1 to give 7-fluoro-4-iodo-1H-indazol-3-amine as yellow solid.

[0223] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.18 (s, 2H), 6.88 (dd, J = 11.1, 7.8 Hz, 1H), 7.28 (dd, J = 8.1, 4.2 Hz, 1H), 12.33 (s, 1H).

Step 2: 6-(3-amino-7-fluoro-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-33)

[0224] 4-iodo-1H-indazol-3-amine was replaced by 7-fluoro-4-iodo-1H-indazol-3-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-33.

[0225] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.43 (s, 2H), 6.88-6.92 (m, 1H), 7.11-7.24 (m, 2H), 7.36-7.42 (m, 2H), 7.65-7.74 (m, 2H), 7.80-7.85 (m, 3H), 8.11 (s, 1H), 8.18 (d, J = 8.1 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 10.62 (s, 1H), 12.34 (s, 1H).

Example 34:

6-(3-amino-7-bromo-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-34)

[0226] 

Step 1: 7-bromo-4-iodo-1H-indazol-3-amine

[0227] 2-fluoro-6-iodobenzonitrile was replaced by 3-bromo-2-fluoro-6-iodobenzonitrile and other raw materials, reagents and preparation method were identical with those in step 5 of example 1 to give 7-bromo-4-iodo-1H-indazol-3-amine as yellow solid.

[0228] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.18 (s, 2H), 7.19 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 7.5 Hz, 1H), 12.18 (s, 1H).

Step 2: 6-(3-amino-7-bromo-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-34)

[0229] 4-iodo-1H-indazol-3-amine was replaced by 7-bromo-4-iodo-1H-indazol-3-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-34.

[0230] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.45 (s, 2H), 6.89 (d, J = 7.5 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.37-7.42 (m, 2H), 7.59 (d, J = 7.2 Hz, 1H), 7.69-7.75 (m, 2H), 7.81-7.85 (m, 3H), 8.15 (s, 1H), 8.19 (d, J = 8.1 Hz, 1H), 8.32 (d, J = 8.7 Hz, 1H), 10.64 (s, 1H), 12.22 (s, 1H).

Example 35:

6-(3-amino-7-methyl-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-35)

[0231] 

Step 1: 4-iodo-7-methyl-1H-indazol-3-amine

[0232] 2-fluoro-6-iodobenzonitrile was replaced by 2-fluoro-6-iodo-3-methylbenzonitrile and other raw materials, reagents and preparation method were identical with those in step 5 of example 1 to give 4-iodo-7-methyl-1H-indazol-3-amine as yellow solid.

[0233] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 2.33 (d, J = 0.9 Hz, 3H), 5.02 (s, 2H), 6.74 (dd, J = 7.5, 1.2 Hz, 1H), 7.24 (d, J = 7.5 Hz, 1H), 11.83 (s, 1H).

Step 2: 6-(3-amino-7-methyl-1H-indazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-35)

[0234] 4-iodo-1H-indazol-3-amine was replaced by 4-iodo-7-methyl-1H-indazol-3-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-35.

[0235] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 2.47 (s, 3H), 4.31 (s, 2H), 6.86 (d, J = 6.9 Hz, 1H), 7.11-7.16 (m, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.64-7.69 (m, 1H), 7.72 (dd, J = 8.4, 1.8 Hz, 1H), 7.78-7.80 (m, 1H), 7.84 (d, J = 7.5 Hz, 2H), 8.10 (d, J = 1.5 Hz, 1H), 8.17 (d, J = 8.1 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 10.63 (s, 1H), 11.88 (s, 1H).

Example 36:

6-(3-amino-1H-indazol-4-yl)-N-(3-methoxyphenyl)-1-naphthalenecarboxamide (I-36)

[0236] 

Step 1: N-(3-methoxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxam ide

[0237] Phenylamine was replaced by m-methoxyphenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-methoxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as brown solid.

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-methoxyphenyl)-1-naphthalenecarboxamide (I-36)

[0238] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-methoxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-36.

[0239] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 3.77 (s, 3H), 4.31 (s, 2H), 6.72 (dd, J = 8.1, 2.4 Hz, 1H), 6.94 (t, J = 3.9 Hz, 1H), 7.26-7.31 (m, 1H), 7.34-7.35 (m, 2H), 7.39 (d, J = 8.4 Hz, 1H), 7.55 (s, 1H), 7.65-7.70 (m, 1H), 7.75 (dd, J = 8.7, 1.5 Hz, 1H), 7.79 (d, J = 7.2 Hz, 1H), 8.13 (d, J = 1.5 Hz, 1H), 8.19 (d, J = 8.7 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 10.61 (s, 1H), 11.83 (s, 1H).

Example 37:

6-(3-amino-1H-indazol-4-yl)-N-(3-(trifluoromethoxy)phenyl)-1-naphthalene-carboxamide (I-37)

[0240] 

Step 1: N-(3-trifluoromethoxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenec arboxamide

[0241] Phenylamine was replaced by m-trifluoromethoxyphenyla mineand other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-trifluoromethoxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenec arboxamide as brown solid.

[0242] ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.40 (s, 12H), 7.05 (dd, J = 8.4, 0.9 Hz, 1H), 7.38-7.43 (m, 1H), 7.49-7.55 (m, 2H), 7.75-7.79 (m, 3H), 7.93 (dd, J = 8.4, 1.2 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 8.32 (d, J = 8.7 Hz, 1H), 8.42 (s, 1H).

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-(trifluoromethoxy)phenyl)-1-naphthalenecarboxamide (I-37)

[0243] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-trifluoromethoxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenec arboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-37.

[0244] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.31 (s, 2H), 6.93-6.96 (m, 1H), 7.12-7.15 (m, 1H), 7.34-7.36 (m, 2H), 7.52 (t, J = 8.1 Hz, 1H), 7.69 (dd, J = 8.1, 7.2 Hz, 1H), 7.74-7.77 (m, 2H), 7.86 (dd, J = 7.2, 0.9 Hz, 1H), 8.03 (s, 1H), 8.14 (d, J = 1.5 Hz, 1H), 8.21 (d, J = 8.4 Hz, 1H), 8.32 (d, J = 8.7 Hz, 1H), 10.92 (s, 1H), 11.83 (s, 1H).

Example 38:

6-(3-amino-1H-indazol-4-yl)-N-(3-hydroxyphenyl)-1-naphthalenecarboxamide (I-38)

[0245] 

Step 1: N-(3-hydroxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxami de

[0246] Phenylamine was replaced by m-hydroxyphenylamineand other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-hydroxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxami de as brown solid.

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-(trifluoromethoxy)phenyl)-1-naphthalenecarboxamide (I-38)

[0247] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-hydroxyphenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxami de and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-38.

[0248] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 6.52-6.56 (m, 1H), 6.97 (dd, J = 4.2, 3.6 Hz, 1H), 7.12-7.20 (m, 2H), 7.37-7.38 (m, 2H), 7.42 (s, 1H), 7.63-7.69 (m, 1H), 7.72-7.77 (m, 2H), 8.12 (d, J = 1.5 Hz, 1H), 8.17 (d, J = 8.1 Hz, 1H), 8.27 (d, J = 8.7 Hz, 1H), 10.51 (s, 1H).

Example 39:

6-(3-amino-1H-indazol-4-yl)-N-(3-nitrophenyl)-1-naphthalenecarboxamide (I-39)

[0249] 

Step 1: N-(3-nitrophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide

[0250] Phenylamine was replaced by m-nitrophenylamine and other raw materials, reagents and preparation method were identical with those in step 4 of example 1 to give N-(3-nitrophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide as brown solid.

Step 2: 6-(3-amino-1H-indazol-4-yl)-N-(3-nitrophenyl)-1-naphthalenecarboxamide (I-39)

[0251] N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide was replaced by N-(3-nitrophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxamide and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-39.

[0252] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.33 (s, 2H), 6.95 (t, J = 3.9 Hz, 1H), 7.34-7.36 (m, 2H), 7.67-7.78 (m, 3H), 7.88 (d, J = 6.9 Hz, 1H), 8.02 (dd, J = 8.1, 1.5 Hz, 1H), 8.15-8.18 (m, 2H), 8.23 (d, J = 8.1 Hz, 1H), 8.35 (d, J = 8.7 Hz, 1H), 8.91 (s, 1H), 11.12 (s, 1H), 11.84 (s, 1H).

Example 40:

6-(3-amino-1H-indazol-4-yl)-N-(3-aminophenyl)-1-naphthalenecarboxamide (I-40)

[0253] 

[0254] 20 mg of 6-(3-amino-1H-indazol-4-yl)-N-(3-nitrophenyl)-1-naphthalenecarboxamide (I-39) was dissloved in 1 ml of ethanol, 25 mg of ammonium chloride in 0.5 ml water and 13 mg of iron powder were added and heated to 70 °C. After stirred for 0.5 h, the mixture was cooled to room temperature, filtered and then concentrated. Water and ethyl acetate were added to separate. The aqueous phase was extracted with ethyl acetate. The combined organic phases was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated to give 13 mg of white solid I-40. Yield: 72%.

[0255] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.31 (s, 2H), 5.16 (s, 2H), 6.34 (dd, J = 7.8, 0.9 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H), 6.93-7.01 (m, 2H), 7.21 (s, 1H), 7.34-7.35 (m, 2H), 7.63-7.68 (m, 1H), 7.72-7.75 (m, 2H), 8.11 (d, J = 1.5 Hz, 1H), 8.16 (d, J = 8.1 Hz, 1H), 8.27 (d, J = 9.0 Hz, 1H), 10.33 (s, 1H), 11.84 (s, 1H).

Example 41:

6-(3-aminobenzo[d]isoxazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-41)

[0256] 

Step 1: 4-iodobenzo[d]isoxazol-3-amine 61 mg of acetohydroxamic acid was dissloved in 1 ml of N,N-dimethylformamide and 91 mg of potassium t-butoxide was added slowly with stirring and stirred for 0.5 h at room temperature. Then 100 mg of 2-fluoro-6-iodobenzonitrile was added slowly and stirred for 12 hours at room temperature. Then 10 ml of water was added and the mixture was filtered. The filter cake was washed with water and dried to give 72 mg of 4-iodobenzo[d]isoxazol-3-amine as white solid. Yield: 69%.

[0257] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.93 (s, 2H), 7.24-7.29 (m, 1H), 7.55 (dd, J = 8.4, 0.6 Hz, 1H), 7.69-7.71 (m, 1H).

Step 2: 6-(3-aminobenzo[d]isoxazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-41)

[0258] 4-iodo-1H-indazol-3-amine was replaced by 4-iodobenzo[d]isoxazol-3-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-41.

[0259] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.23 (s, 2H), 7.14 (t, J = 7.5 Hz, 1H), 7.30 (dd, J = 7.2, 0.9 Hz, 1H), 7.37-7.42 (m, 2H), 7.59 (dd, J = 8.1, 0.6 Hz, 1H), 7.64-7.72 (m, 2H), 7.77 (dd, J = 8.4, 1.5 Hz, 1H), 7.83-7.85 (m, 3H), 8.19-8.21 (m, 2H), 8.35 (d, J = 8.7 Hz, 1H), 10.63 (s, 1H).

Example 42:

6-(3-amino-7-fluorobenzo[d]isoxazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-42)

[0260] 

Step 1: 7-fluoro-4-iodobenzo[d]isoxazol-3-amine

[0261] 2-fluoro-6-iodobenzonitrile was replaced by 2,3-difluoro-6-iodobenzonitrile and other raw materials, reagents and preparation method were identical with those in step 1 of example 41 to give 7-fluoro-4-iodobenzo[d]isoxazol-3-amine as white solid.

Step 2: 6-(3-amino-7-fluorobenzo[d]isoxazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-42)

[0262] 4-iodo-1H-indazol-3-amine was replaced by 7-fluoro-4-iodobenzo[d]isoxazol-3-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give yellow solid I-42.

[0263] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.41 (s, 2H), 7.11-7.16 (m, 1H), 7.26-7.30 (m, 1H), 7.39 (t, J = 7.5 Hz, 2H), 7.58-7.76 (m, 3H), 7.82-7.85 (m, 3H), 8.18-8.20 (m, 2H), 8.35 (d, J = 8.7 Hz, 1H), 10.63 (s, 1H).

Example 43:

6-(3-amino-7-methylbenzo[d]isoxazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-43)

[0264] 

Step 1: 4-iodo-7-methylbenzo[d]isoxazol-3-amine

[0265] 2-fluoro-6-iodobenzonitrile was replaced by 2-fluoro-6-iodo-3-methylbenzonitrile and other raw materials, reagents and preparation method were identical with those in step 1 of example 41 to give 4-iodo-7-methylbenzo[d]isoxazol-3-amine as white solid.

[0266] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 2.35 (s, 3H), 5.91 (s, 2H), 7.09 (dd, J = 7.5, 0.9 Hz, 1H), 7.58 (d, J = 7.2 Hz, 1H).

Step 2: 6-(3-amino-7-methylbenzo[d]isoxazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-43)

[0267] 4-iodo-1H-indazol-3-amine was replaced by 4-iodo-7-methylbenzo[d]isoxazol-3-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-43.

[0268] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 5.22 (s, 2H), 7.14 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 7.5 Hz, 1H), 7.40 (t, J = 8.1 Hz, 2H), 7.48 (d, J = 7.5 Hz, 1H), 7.67-7.76 (m, 2H), 7.83-7.85 (m, 3H), 8.16-8.21 (m, 2H), 8.34 (d, J = 8.7 Hz, 1H), 10.63 (s, 1H).

Example 44:

6-(3-amino-7-methoxybenzo[d]isoxazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (I-44)

[0269] 

Step 1: 4-iodo-7-methoxybenzo[d]isoxazol-3-amine

[0270] 2-fluoro-6-iodobenzonitrile was replaced by 2-fluoro-6-iodo-3-methoxybenzonitrile and other raw materials, reagents and preparation method were identical with those in step 1 of example 41 to give 4-iodo-7-methoxybenzo[d]isoxazol-3-amine as white solid.

[0271] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 3.91 (s, 3H), 5.91 (s, 2H), 6.91 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 8.1 Hz, 1H).

Step 2: 6-(3-amino-7-methoxybenzo[d]isoxazol-4-yl)-N-phenyl-1-naphthalenecarboxamide (1-44)

[0272] 4-iodo-1H-indazol-3-amine was replaced by 4-iodo-7-methoxybenzo[d]isoxazol-3-amine and other raw materials, reagents and preparation method were identical with those in step 6 of example 1 to give white solid I-44.

[0273] ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 4.00 (s, 3H), 5.23 (s, 2H), 7.14 (t, J = 7.5 Hz, 1H), 7.20-7.26 (m, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.65-7.74 (m, 2H), 7.81-7.85 (m, 3H), 8.13 (s, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 10.61 (s, 1H).

Example 45:

Effect of the compound on the activity of VEGFR-2 at molecular level

1. Experimental method

[0274] The enzyme reaction substrate Poly(Glu, Tyr)4:1 was diluted with potassium-free PBS (10 mM sodium phosphate buffer, 150mM NaCl, pH 7.2-7.4) to 20 µg/ml and microwell plate was coated with 125 ml/well mixture. The reaction was carried out at 37 °C for 12-16 h. Then the liquid was discarded and the microwell plate was washed with 200ml/well T-PBS (PBS containing 0.1% Tween-20) three times, 5 minutes each. The microwell plate was dried for 1-2 hours at 37 °C oven. Each well was added with reaction buffer (50 mM HEPES, pH 7.4, 50 mM MgCl₂, 5 mM MnCl₂, 0.2 mM Na₃VO₄, 1 mM DTT) diluted ATP solution (50 mL) whose final concentration is 5 µM. Drug was diluted with 1% DMSO to a suitable concentration. 10 µl /well of drug was added and then 40 µl reaction buffer diluted VEGFR-2 tyrosine kinase protein was added. The microwell plate was placed into a shaker (100 rpm) and the reaction was carried out at 37 °C for 1 h. The microwell plate was washed with T-PBS three times. Three enzyme-free control wells and corresponding concentration of DMSO control wells were required for each experiment. 100 ml of primary antibody PY99 (p-Tyr (PY99), Cell Signaling Technology, diluted with T-PBS containing 5 mg/ml BSA, 1: 1000 dilution) was added to each well and the plate was placed into a shaker to react for 0.5 h at 37 °C. The plate was washed with T-PBS three times. 100 ml of secondary antibody horseradish peroxidase-labeled goat anti-mouse IgG (diluted with T-PBS containing 5 mg/ml BSA, 1: 2000 dilution) was added to each well and the plate was placed into a shaker to react for 0.5 h at 37 °C. The plate was washed with T-PBS three times. 100 ml of 2 mg/ml of OPD developing solution (diluted with 0.1 M citric acid - sodium citrate buffer containing 0.03% of H₂O₂ (pH = 5.4)) was added to each well and the reaction was carried out at 25 °C in the dark for 1-10 minutes. OPD was dissolved under ultrasound and developing solution was freshly prepared. 50 ml of 2 M H2SO4 was added to each well to quench the reaction and OD value was measured by wavelength tunable microplate reader SPECTRA MAX 190. Wavelength was 490 nm.

[0275] Inhibition rate of the compound was obtained by the following formula:

[0276] IC₅₀ values were calculated by inhibition curves with four parameters fitting.

2. Experimental results

[0277] Enzyme activity assay at molecular level showed that naphthylamide compounds of the present invention at nanomolar concentration have good inhibitory effect on VEGFR-2 tyrosine kinase. Half VEGFR-2 inhibitory concentration of some compounds was about 1 nM and better than positive control compounds SU11248 and ABT869. The compounds of the present invention were potent VEGFR-2 tyrosine kinase inhibitors.

Table 2: Half inhibitory concentration of compounds in examples of the preset invention for receptor tyrosine kinase VEGFR-2

Compound	IC50 (nM)
SU11248 a	7.4
ABT869 b	6.2
I-1	1.6
I-2	7.0
I-3	7.1
I-4	1.5
I-5	1.3
I-6	26.7
I-7	7.3
I-8	1.9
I-9	18.2
I-10	18.7
I-11	7.1
I-12	9.2
I-13	92.5
I-14	10.8
I-15	48.4
I-16	24.0
I-17	1.4
I-18	2.5
I-19	7.3
I-20	3.8
I-21	8.1
I-22	7.6
I-23	4.5
I-24	9.7
I-25	20.2
I-26	101.3
I-27	95.2
I-28	8.6

aSU11248, positive control (Mendel, D. B. et al., Clin. Cancer Res. 2003; 9 (1): 327-37.) bABT869, positive control (Dai, Y. et al., J. Med. Chem. 2007; 50 (7): 1584-97.)

Example 46:

[0278] Effect of compound at cellular level on VEGF-induced human umbilical vein endothelial cells (HUVEC) proliferation

1. Experimental method

[0279] 5000-8000 primary HUVEC cells before 5-15 doublings were seeded to each well of 96-well plate and each well contained 90 µl. The cells were cultured overnight and then starved with 90 µl/well serum-free basal culture medium for 24 h. Then 10 µl different concentration of compound was added to each well. Five concentrations were set and each concentration had 3 wells. After 2 h, 100 ng/mL of VEGF growth-stimulating factor was added. After 48 h, the medium was discarded, the cells were fixed with pre-cooled 10% TCA at 4 °C for 1 h, then washed with distilled water five times and dried in air. Then 100 µl of 4 mg/ml of sulforodamine B (SRB) solution prepared from 1% acetic acid was added to each well to dye 15 minutes at room temperature. The staining solution was discarded and each well was washed with 1% acetic acid five times and then dried in air. Finally, each well was added with 150 µl Tris-HCl solution (10mM Tris, pH 10.0) and absorbance OD values at 560nm were measured by microplate reader. Inhibition rate of the compound on HUVEC cell proliferation was measured to reflect VEGF-mediated proliferation inhibition effect of compound.

[0280] Inhibition rate of the compound was obtained by the following formula:

[0281] IC₅₀ values were calculated by inhibition curves with four parameters fitting.

2. Experimental results

[0282] It can be seen from the data in table 3 that half inhibitory concentrations of most of naphthylamide compounds of the present invention for VEGF-induced human umbilical vein endothelial cells (HUVEC) proliferation were in the nanomolar level, wherein cell activities of compounds I-4, I -8, I-9, I-14 and I-21 were stronger than that of positive control compound ABT869.

Table 3: Half inhibitory concentrations of compounds in examples of the present invention for VEGF-induced human umbilical vein endothelial cells (HUVEC) proliferation

Compound in the example	IC50 (nM)
ABT869	2.32
I-1	3.76
I-2	20.54
I-3	20.17
I-4	0.9
I-6	86.36
I-7	2.08
I-8	1.3
I-9	1.44
I-10	6.1
I-11	2.26
I-12	16.99
I-13	2.63
I-14	1.57
I-15	3.12
I-16	3.86
I-17	>100
I-18	>100
I-19	>100
I-20	6.09
I-21	1.53
I-22	3.261
I-23	4.456
I-24	5.72
I-26	6.96
I-27	2.79

Claims

1. A compound as represented by general formula (I), medicinal salts and hydrates or solvates thereof:

wherein, R₁ is located at position 6 on the naphthalene ring, and the compound is a compound represented by following general formula (II):



is located at position 1 on the naphthalene ring;

R₃ is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-10 membered heteroaryl containing 1-5 hetero atoms selected from N, O and S; in the case of substitution, the substituent is 1 to 3 substituents and each substituent is independently selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, hydroxy, amino, nitro and halogen;

R₂ is located at any one of positions 1-8 on the naphthalene ring except R₁ and is hydrogen or halogen;

, and

Z is C(R₅)=CH, S or O;

Y is NH, NMe, O, CH=C(R₆) or CH=N;

R₅ is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl and C1-C3 alkoxy, preferably from the group consisting of hydrogen, F, Cl, Br, methyl and methoxy;

R6 is selected from the group consisting of hydrogen, pyrazolyl, C1-C3 alkyl-substituted pyrazolyl and C1-C3 hydroxyalkyl-substituted pyrazolyl, preferably from the group consisting of hydrogen, pyrazolyl, methyl-substituted pyrazolyl and hydroxyethyl-substituted pyrazolyl.

2. The compound, medicinal salts and hydrates or solvates thereof of claim 1, wherein, the compound is a compound represented by general formula (III), (IV), (V) or (VI):

wherein,

is located at position 1 on the naphthalene ring; R₂ and R₃ are defined as described in claim 1; R₄ is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl and C1-C3 alkoxy, preferably from the group consisting of hydrogen, F, Cl, Br, methyl and methoxy;

V is S or O;

W is N or C(R₇);

R₇ is selected from the group consisting of hydrogen, pyrazolyl, C1-C3 alkyl-substituted pyrazolyl and C1-C3 hydroxyalkyl-substituted pyrazolyl, preferably from the group consisting of hydrogen, pyrazolyl, methyl-substituted pyrazolyl and hydroxyethyl-substituted pyrazolyl.

3. The compound, medicinal salts, and hydrates or solvates thereof of claim 1, wherein, R₁ is any one of the following structures:

wherein, R₄ is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl and C1-C3 alkoxy.

4. The compound, medicinal salts, and hydrates or solvates thereof of claim 1, wherein, R₃ is selected from the group consisting of hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl, a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-6 membered heteroaryl containing 1-3 hetero atoms selected from N, O and S; in the case of substitution, the substituent may be 1 to 3 substituents and each substituent is independently selected from the group consisting of C1-C3 alkyl, methoxy, trifluoromethyl, trifluoromethoxy, hydroxy, amino, nitro, F, Cl and Br;

R2 is located at any one of positions 1-8 on the naphthalene ring except R₁ and

, and is hydrogen, F, Cl or Br;

and R₁ is any one of the following structures:

wherein, R₄ is selected from the group consisting of hydrogen, halogen, C1-C3 alkyl and C1-C3 alkoxy.

5. The compound, medicinal salts, and hydrates or solvates thereof of claim 1, wherein, R₁ is any one of the following structures:

wherein, R₄ is selected from the group consisting of hydrogen, F, Cl, Br, methyl and methoxy.

6. The compound, medicinal salts and hydrates or solvates thereof of claim 1 or 2, wherein, the compound is selected from the group consisting of the following compounds:

7. A pharmaceutical composition comprising a therapeutically effective amount of one or more of compounds, pharmaceutically acceptable salts, hydrates and solvates thereof of any one of claims 1-6 and optionally a pharmaceutically acceptable carrier.

8. Compounds pharmaceutically acceptable salts, hydrates and solvates thereof of any one of claims 1-6 and the pharmaceutical composition of claim 7 for use for preventing and/or treating abnormal angiogenesis-related diseases, preferably as protein tyrosine kinase inhibitors, especially as VEGFR-2 inhibitors;the abnormal angiogenesis-related disease is selected from the group consisting of tumor, rheumatoid arthritis, age-related macular degeneration and psoriasis.

9. Compounds of any one of claims 1-6 for use of claim 8, wherein, the tumor includes lung cancer, breast cancer, colon cancer, prostate cancer, pancreas cancer, stomach cancer, liver cancer, ovarian cancer, renal cancer, glioma, melanoma, pancreatic cancer, head and neck cancer, bladder cancer, cervical cancer, cholangiocarcinoma, nasopharyngeal cancer, thyroid cancer, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, fibrosarcoma, leiomyosarcoma, myeloma and lymphoma.

Ansprüche

1. Verbindung, dargestellt durch die allgemeine Formel (I), medizinische Salze und Hydrate oder Solvate davon:

wobei R1 an Position 6 des Naphthalinrings liegt und die Verbindung eine Verbindung dargestellt durch folgende allgemeine Formel (II) ist:



liegt an Position 1 des Naphthalinrings;

R₃ ist ausgewählt aus der Gruppe bestehend aus Wasserstoff, C1-C6-Alkyl, C3-C6-Cycloalkyl, einem substituierten oder unsubstituierten Phenyl und einem substituierten oder unsubstituierten 5-10-gliedrigen Heteroaryl enthaltend 1-5-Heteroatome ausgewählt aus N, O und S; im Fall einer Substitution der Substituent 1 bis 3 Substituenten ist und jeder Substituent voneinander unabhängig ausgewählt ist aus der Gruppe bestehend aus C1-C3-Alkyl, C1-C3-Alkoxy, C1-C3-Halogenalkyl, C1-C3-Haloaloxy, Hydroxy, Amino, Nitro und Halogen;

R₂ an einer der Positionen 1 - 8 des Naphthalinrings liegt mit Ausnahme von R₁ und

und Wasserstoff oder Halogen ist;

Z C(R₅)=CH, S oder O ist;

Y NH, NMe, O, CH=C(R₆) oder CH=N ist;

R₅ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, Halogen, C1-C3-Alkyl und C1-C3-Alkoxy, vorzugsweise aus der Gruppe bestehend aus Wasserstoff, F, Cl, Br, Methyl und Methoxy;

R₆ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, Pyrazolyl, C1-C3-Alkyl-substituiertem Pyrazolyl und C1-C3-Hydroxyalkyl-substituiertem Pyrazolyl, vorzugsweise aus der Gruppe bestehend aus Wasserstoff, Pyrazolyl, Methylsubstituiertem Pyrazolyl und Hydroxyethyl-substituiertem Pyrazolyl.

2. Verbindung, medizinische Salze und Hydrate oder Solvate desselben nach Anspruch 1, wobei die Verbindung eine Verbindung dargestellt durch die allgemeinen Formeln (III), (IV), (V) oder (VI) ist:



wobei,

an der Position 1 des Naphthalinrings liegt; R₂ und R₃ wie in Anspruch 1 beschrieben definiert sind; R₄ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, Halogen, C1-C3-Alkyl und C1-C3-Alkoxy, vorzugsweise aus der Gruppe bestehend aus Wasserstoff, F, Cl, Br, Methyl und Methoxy;

V S oder O ist;

W N oder C(R₇) ist;

wobei R₇ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, Pyrazolyl, C1-C3-Alkyl-substituiertem Pyrazolyl und C1-C3-Hydroxyalkyl-substituiertem Pyrazolyl, vorzugsweise aus der Gruppe bestehend aus Wasserstoff, Pyrazolyl, Methylsubstituiertem Pyrazolyl und Hydroxyethyl-substituiertem Pyrazolyl.

3. Verbindung, medizinische Salze und Hydrate oder Solvate desselben nach Anspruch 1, wobei R₁ eine der folgenden Strukturen ist:



wobei R₄ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, Halogen, C1-C3-Alkyl und C1-C3-Alkoxy.

4. Verbindung, medizinische Salze und Hydrate oder Solvate desselben nach Anspruch 1, wobei R₃ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, C1-C3-Alkyl, C1-C6-Cycloalkyl, einem substituierten oder unsubstituierten Phenyl und einem substituierten oder unsubstituierten 5-6-gliedrigen Heteroaryl enthaltend 1-3-Heteroatome ausgewählt aus N, O und S; im Fall einer Substitution der Substituent 1 bis 3 Substituenten sein kann und jeder Substituent voneinander unabhängig ausgewählt ist aus der Gruppe bestehend aus C1-C3-Alkyl, Methoxy, Trifluoromethyl, Trifluoromethoxy, Hydroxy, Amino, Nitro, F, Cl und Br;

R₂ an einer der Positionen 1 - 8 auf dem Naphthalinring liegt mit Ausnahme von R₁ und

und Wasserstoff, F, Cl oder Br ist;

und R₁ eine der folgenden Strukturen ist:

wobei R₄ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, Halogen, C1-C3-Alkyl und C1-C3-Alkoxy.

5. Verbindung, medizinische Salze und Hydrate oder Solvate desselben nach Anspruch 1, wobei R₁ eine der folgenden Strukturen ist:

wobei R₄ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, F, Cl, Br, Methyl und Methoxy.

6. Verbindung, medizinische Salze und Hydrate oder Solvate desselben nach Anspruch 1 oder 2, wobei die Verbindung ausgewählt ist aus der Gruppe bestehend aus den folgenden Verbindungen:

7. Pharmazeutische Verbindung umfassend eine therapeutisch effektive Menge einer oder mehrerer Verbindungen, pharmazeutisch akzeptabler Salze, Hydrate und Solvate davon gemäß einem der Ansprüche 1 bis 6 und optional einen pharmazeutisch akzeptablen Träger.

8. Verbindungen pharmazeutisch akzeptabler Salze, Hydrate und Solvate davon gemäß einem der Ansprüche 1 bis 6 und die pharmazeutische Zusammensetzung nach Anspruch 7 zur Verwendung zum Vorbeugen und/oder Behandeln von mit abnormaler Angiogenese zusammenhängenden Krankheiten, vorzugsweise als Proteintyrosinkineaseinhibitoren, insbesondere als VEGFR-2-Inhibitoren; wobei die mit abnormaler Angiogenese zusammenhängende Krankheit ausgewählt ist aus der Gruppe bestehend aus Tumor, rheumatoider Arthritis, altersbedingter Maculardegeneration und Psoriasis.

9. Verbindungen nach einem der Ansprüche 1 bis 6 zur Verwendung nach Anspruch 8, wobei der Tumor Lungenkrebs, Brustkrebs, Darmkrebs, Prostatakrebs, Pankreaskrebs, Magenkrebs, Leberkrebs, Eierstrockkrebs, Nierenkrebs, Gliom, Melanom, Bauchspeicheldrüsenkrebs, Kopf- und Halskrebs, Blasenkrebs, Gebärmutterhalskrebs, Gallengangskarzinom, Nasen-Rachen-Krebs, Schilddrüsenkrebs, Osteosarkom, Synovialsarkom, Rhabdomyosarkom, Fibrosarkom, Leiomyosarkom, Myelom und Lymphom beinhaltet.

Revendications

1. Composé représenté par la formule générale (I), ses sels à usage médical, et leurs hydrates ou solvates :

dans lesquels R₁ est situé à la position 6 sur le cycle naphtalène, et le composé est un composé représenté par la formule générale (II) suivante :



est situé à la position 1 sur le cycle naphtalène ;

R₃ est choisi dans l'ensemble constitué par un hydrogène, alkyle en C₁ à C₆, cycloalkyle en C₃ à C₆, phényle substitué ou non substitué, et hétéroaryle à 5 à 10 chaînons substitué ou non substitué contenant 1 à 5 hétéroatomes choisis parmi N, O et S ; dans le cas d'une substitution, le substituant est 1 à 3 substituants et chaque substituant est indépendamment choisi dans l'ensemble constitué par un halogène, alkyle en C₁ à C₃, alcoxy en C₁ à C₃, halogénoalkyle en C₁ à C₃, halogénoalcoxy en C₁ à C₃, hydroxy, amino et nitro ;

R₂ est situé à l'une quelconque des positions 1 à 8 sur le cycle naphtalène à l'exception de R₁ et

et est un hydrogène ou halogène ;

Z est C(R₅)=CH, S ou O ;

Y est NH, NMe, 0, CH=C(R₆) ou CH=N ;

R₅ est choisi dans l'ensemble constitué par un hydrogène, halogène, alkyle en C₁ à C₃ et alcoxy en C₁ à C₃, de préférence dans l'ensemble constitué par un hydrogène, F, Cl, Br, méthyle et méthoxy ;

R₆ est choisi dans l'ensemble constitué par un hydrogène, pyrazolyle, pyrazolyle à substitution alkyle en C₁ à C₃, et pyrazolyle à substitution hydroxyalkyle en C₁ à C₃, de préférence dans l'ensemble constitué par un hydrogène, pyrazolyle, pyrazolyle à substitution méthyle, et pyrazolyle à substitution hydroxyéthyle.

2. Composé, ses sels à usage médical, et leurs hydrates ou solvates, selon la revendication 1, dans lesquels le composé est un composé représenté par la formule générale (III), (IV), (V) ou (VI) :

dans lesquels

est situé à la position 1 sur le cycle naphtalène ; R₂ et R₃ sont tels que définis dans la revendication 1 ; R₄ est choisi dans l'ensemble constitué par un hydrogène, halogène, alkyle en C₁ à C₃ et alcoxy en C₁ à C₃, de préférence dans l'ensemble constitué par un hydrogène, F, Cl, Br, méthyle et méthoxy ;

V est S ou O ;

W est N ou C(R₇) ;

R₇ est choisi dans l'ensemble constitué par un hydrogène, pyrazolyle, pyrazolyle à substitution alkyle en C₁ à C₃, et pyrazolyle à substitution hydroxyalkyle en C₁ à C₃, de préférence dans l'ensemble constitué par un hydrogène, pyrazolyle, pyrazolyle à substitution méthyle, et pyrazolyle à substitution hydroxyéthyle.

3. Composé, ses sels à usage médical, et leurs hydrates ou solvates, selon la revendication 1, dans lesquels R₁ est l'une quelconque des structures suivantes



dans lesquels R₄ est choisi dans l'ensemble constitué par un hydrogène, halogène, alkyle en C₁ à C₃ et alcoxy en C₁ à C₃.

4. Composé, ses sels à usage médical, et leurs hydrates ou solvates, selon la revendication 1, dans lesquels R₃ est choisi dans l'ensemble constitué par un hydrogène, alkyle en C₁ à C₃, cycloalkyle en C₃ à C₆, phényle substitué ou non substitué, et hétéroaryle à 5 ou 6 chaînons substitué ou non substitué contenant 1 à 3 hétéroatomes choisis parmi N, O et S ; dans le cas d'une substitution, le substituant peut être 1 à 3 substituants et chaque substituant est indépendamment choisi dans l'ensemble constitué par alkyle en C₁ à C₃, méthoxy, trifluorométhyle, trifluorométhoxy, hydroxy, amino, nitro, F, Cl et Br ;

R₂ est situé à l'une quelconque des positions 1 à 8 sur le cycle naphtalène à l'exception de R₁ et

et est un hydrogène, F, Cl ou Br ;

et R₁ est l'une quelconque des structures suivantes :

et dans lesquels R₄ est choisi dans l'ensemble constitué par un hydrogène, halogène, alkyle en C₁ à C₃ et alcoxy en C₁ à C₃.

5. Composé, ses sels à usage médical, et leurs hydrates ou solvates, selon la revendication 1, dans lesquels R₁ est l'une quelconque des structures suivantes

et dans lesquels R₄ est choisi dans l'ensemble constitué par un hydrogène, F, Cl, Br, méthyle et méthoxy.

6. Composé, ses sels à usage médical, et leurs hydrates ou solvates, selon la revendication 1 ou 2, dans lesquels le composé est choisi dans l'ensemble constitué par les composés suivants :

7. Composition pharmaceutique comprenant une quantité efficace du point de vue thérapeutique d'un ou plusieurs composés, sels pharmaceutiquement acceptables, hydrates et solvates de ceux-ci selon l'une quelconque des revendications 1 à 6, et éventuellement un véhicule pharmaceutiquement acceptable.

8. Composés, sels pharmaceutiquement acceptables, hydrates et solvates de ceux-ci, selon l'une quelconque des revendications 1 à 6, et composition pharmaceutique selon la revendication 7, pour une utilisation pour prévenir et/ou traiter des maladies associées à une angiogenèse anormale, de préférence en tant qu'inhibiteurs de protéine tyrosine kinase, en particulier en tant qu'inhibiteurs de VEGFR-2 ; la maladie associée à une angiogenèse anormale étant choisie dans l'ensemble constitué par une tumeur, une polyarthrite rhumatoïde, une dégénérescence maculaire liée à l'âge, et un psoriasis.

9. Composés selon l'une quelconque des revendications 1 à 6 pour une utilisation selon la revendication 8, dans lesquels la tumeur comprend un cancer du poumon, un cancer du sein, un cancer du côlon, un cancer de la prostate, un cancer du pancréas, un cancer de l'estomac, un cancer du foie, un cancer ovarien, un cancer rénal, un gliome, un mélanome, un cancer pancréatique, un cancer de la tête et du cou, un cancer de la vessie, un cancer du col, un cholangiocarcinome, un cancer naso-pharyngé, un cancer de la thyroïde, un ostéosarcome, un sarcome synovial, un rhabdomyosarcome, un fibrosarcome, un leiomyosarcome, un myélome et un lymphome.